Stryker (SYK) 10-K 11 Feb 21 2020 FY Annual report Financial data

COVER PAGE

COVER PAGE - USD ($)	12 Months Ended
	Dec. 31, 2020	Jan. 31, 2021	Jun. 30, 2020
Entity Information [Line Items]
Document Type	10-K
Document Annual Report	true
Document Period End Date	Dec. 31, 2020
Document Transition Report	false
Entity File Number	001-13149
Entity Registrant Name	STRYKER CORP
Entity Incorporation, State or Country Code	MI
Entity Tax Identification Number	38-1239739
Entity Address, Address Line One	2825 Airview Boulevard,
Entity Address, City or Town	Kalamazoo,
Entity Address, State or Province	MI
Entity Address, Postal Zip Code	49002
City Area Code	(269)
Local Phone Number	385-2600
Title of 12(g) Security	None
Entity Well-known Seasoned Issuer	Yes
Entity Voluntary Filers	No
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Large Accelerated Filer
Entity Emerging Growth Company	false
Entity Small Business	false
ICFR Auditor Attestation Flag	true
Entity Shell Company	false
Entity Public Float			$ 63,413,151,504
Entity Common Stock, Shares Outstanding		376,200,942
Documents Incorporated by Reference	Portions of the proxy statement to be filed with the U.S. Securities and Exchange Commission relating to the 2021 Annual Meeting of Shareholders (the 2021 proxy statement) are incorporated by reference into Part III.
Amendment Flag	false
Document Fiscal Year Focus	2020
Document Fiscal Period Focus	FY
Entity Central Index Key	0000310764
Current Fiscal Year End Date	--12-31
Common Stock, $.10 Par Value
Entity Information [Line Items]
Title of 12(b) Security	Common Stock, $.10 Par Value
Trading Symbol	SYK
Security Exchange Name	NYSE
1.125% Notes due 2023
Entity Information [Line Items]
Title of 12(b) Security	1.125% Notes due 2023
Trading Symbol	SYK23
Security Exchange Name	NYSE
0.250% Notes due 2024
Entity Information [Line Items]
Title of 12(b) Security	0.250% Notes due 2024
Trading Symbol	SYK24A
Security Exchange Name	NYSE
2.125% Notes due 2027
Entity Information [Line Items]
Title of 12(b) Security	2.125% Notes due 2027
Trading Symbol	SYK27
Security Exchange Name	NYSE
0.750% Notes due 2029
Entity Information [Line Items]
Title of 12(b) Security	0.750% Notes due 2029
Trading Symbol	SYK29
Security Exchange Name	NYSE
2.625% Notes due 2030
Entity Information [Line Items]
Title of 12(b) Security	2.625% Notes due 2030
Trading Symbol	SYK30
Security Exchange Name	NYSE
1.000% Notes due 2031
Entity Information [Line Items]
Title of 12(b) Security	1.000% Notes due 2031
Trading Symbol	SYK31
Security Exchange Name	NYSE

Consolidated Statements Of Earn

Consolidated Statements Of Earnings - USD ($) shares in Millions, $ in Millions	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018
Income Statement [Abstract]
Net sales	$ 14,351	$ 14,884	$ 13,601
Cost of sales	5,294	5,188	4,663
Gross profit	9,057	9,696	8,938
Research, development and engineering expenses	984	971	862
Selling, general and administrative expenses	5,361	5,356	5,099
Recall charges	17	192	23
Amortization of intangible assets	472	464	417
Total operating expenses	6,834	6,983	6,401
Operating income	2,223	2,713	2,537
Other income (expense), net	(269)	(151)	(181)
Earnings before income taxes	1,954	2,562	2,356
Income taxes	355	479	(1,197)
Net earnings	$ 1,599	$ 2,083	$ 3,553
Net earnings per share of common stock:
Basic net earnings per share of common stock (in dollars per share)	$ 4.26	$ 5.57	$ 9.50
Diluted net earnings per share of common stock (in dollars per share)	$ 4.20	$ 5.48	$ 9.34
Weighted-average shares outstanding (in millions):
Basic (in shares)	375.5	374	374.1
Effect of dilutive employee stock compensation (in shares)	4.8	5.9	6.2
Diluted (in shares)	380.3	379.9	380.3

Consolidated Statements of Comp

Consolidated Statements of Comprehensive Income - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018
Statement of Comprehensive Income [Abstract]
Net earnings	$ 1,599	$ 2,083	$ 3,553
Other comprehensive income (loss), net of tax
Marketable securities	0	1	0
Pension plans	(80)	(42)	(3)
Unrealized gains (losses) on designated hedges	(57)	(3)	22
Financial statement translation	(414)	69	(97)
Total other comprehensive income (loss), net of tax	(551)	25	(78)
Comprehensive income	$ 1,048	$ 2,108	$ 3,475

Consolidated Balance Sheets

Consolidated Balance Sheets - USD ($) $ in Millions	Dec. 31, 2020	Dec. 31, 2019
Current assets
Cash and cash equivalents	$ 2,943	$ 4,337
Marketable securities	81	88
Accounts receivable, less allowance of $131 ($88 in 2019)	2,701	2,893
Inventories:
Materials and supplies	678	677
Work in process	251	178
Finished goods	2,565	2,125
Total inventories	3,494	2,980
Prepaid expenses and other current assets	488	760
Total current assets	9,707	11,058
Property, plant and equipment:
Land, buildings and improvements	1,546	1,263
Machinery and equipment	3,636	3,451
Total property, plant and equipment	5,182	4,714
Less allowance for depreciation	2,430	2,147
Property, plant and equipment, net	2,752	2,567
Goodwill	12,778	9,069
Other intangibles, net	5,554	4,227
Noncurrent deferred income tax assets	1,530	1,575
Other noncurrent assets	2,009	1,671
Total assets	34,330	30,167
Current liabilities
Accounts payable	810	675
Accrued compensation	925	955
Income taxes	207	171
Dividend payable	237	213
Accrued product liabilities	515	331
Accrued expenses and other liabilities	1,586	1,196
Current maturities of debt	761	859
Total current liabilities	5,041	4,400
Long-term debt, excluding current maturities	13,230	10,231
Income taxes	990	1,068
Other noncurrent liabilities	1,985	1,661
Total liabilities	21,246	17,360
Shareholders' equity
Common stock, $0.10 par value	38	37
Additional paid-in capital	1,741	1,628
Retained earnings	12,462	11,748
Accumulated other comprehensive loss	(1,157)	(606)
Total shareholders' equity	13,084	12,807
Total liabilities & shareholders' equity	$ 34,330	$ 30,167

Consolidated Balance Sheets (Pa

Consolidated Balance Sheets (Parentheticals) - USD ($) $ in Millions	Dec. 31, 2020	Dec. 31, 2019
Statement of Financial Position [Abstract]
Accounts receivable, allowance	$ 131	$ 88
Common stock, par value (in dollars per share)	$ 0.10	$ 0.10

Consolidated Statements Of Shar

Consolidated Statements Of Shareholders' Equity - USD ($) shares in Millions, $ in Millions	Total	Total Stryker shareholders' equity	Common Stock	Additional Paid-In Capital	Retained Earnings	Retained EarningsCumulative Effect, Period of Adoption, Adjustment	Accumulated Other Comprehensive Income (Loss)	Non-controlling interest
Beginning balance at Dec. 31, 2017			$ 37	$ 1,496	$ 8,986	$ (759)	$ (553)	$ 14
Beginning balance, shares at Dec. 31, 2017			374.4
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Issuance of common stock under stock compensation and benefit plans			$ 0	(49)
Issuance of common stock under stock compensation and benefit plans, shares			1.9
Repurchase of common stock			$ 0	(7)	(293)
Repurchase of common stock, shares			(1.9)
Share-based compensation				119
Net earnings	$ 3,553				3,553			0
Cash dividends declared					(722)
Other comprehensive income (loss)	(78)						(78)
Interest purchased								(15)
Ending balance, shares at Dec. 31, 2018			374.4
Ending balance at Dec. 31, 2018	11,730	$ 11,730	$ 37	1,559	10,765	0	(631)	0
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Foreign currency exchange translation adjustment								1
Issuance of common stock under stock compensation and benefit plans			$ 0	(50)
Issuance of common stock under stock compensation and benefit plans, shares			2
Repurchase of common stock			$ 0	(8)	(299)
Repurchase of common stock, shares			(1.9)
Share-based compensation				127
Net earnings	2,083				2,083			0
Cash dividends declared					(801)
Other comprehensive income (loss)	25						25
Interest purchased								0
Ending balance, shares at Dec. 31, 2019			374.5
Ending balance at Dec. 31, 2019	12,807	12,807	$ 37	1,628	11,748	$ 0	(606)	0
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Foreign currency exchange translation adjustment								0
Issuance of common stock under stock compensation and benefit plans			$ 1	(29)
Issuance of common stock under stock compensation and benefit plans, shares			1.6
Repurchase of common stock			$ 0	0	0
Repurchase of common stock, shares			0
Share-based compensation				142
Net earnings	1,599				1,599			0
Cash dividends declared					(885)
Other comprehensive income (loss)	(551)
Interest purchased								0
Ending balance, shares at Dec. 31, 2020			376.1
Ending balance at Dec. 31, 2020	$ 13,084	$ 13,084	$ 38	$ 1,741	$ 12,462		$ (1,157)	0
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Foreign currency exchange translation adjustment								$ 0

Consolidated Statements Of Cash

Consolidated Statements Of Cash Flows - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018
Operating activities
Net earnings	$ 1,599	$ 2,083	$ 3,553
Adjustments to reconcile net earnings to net cash provided by operating activities:
Depreciation	340	314	306
Amortization of intangible assets	472	464	417
Asset impairments	215	16	14
Share-based compensation	142	127	119
Recall charges	17	192	23
Sale of inventory stepped up to fair value at acquisition	48	67	16
Deferred income tax (benefit) expense	48	126	(1,582)
Changes in operating assets and liabilities:
Accounts receivable	354	(563)	(60)
Inventories	27	(400)	(385)
Accounts payable	100	63	116
Accrued expenses and other liabilities	(54)	113	289
Recall-related payments	(17)	(177)	(90)
Income taxes	(16)	(105)	(156)
Other, net	2	(129)	30
Net cash provided by operating activities	3,277	2,191	2,610
Investing activities
Acquisitions, net of cash acquired	(4,222)	(802)	(2,451)
Purchases of marketable securities	(54)	(74)	(226)
Proceeds from sales of marketable securities	61	69	394
Purchases of property, plant and equipment	(487)	(649)	(572)
Other investing, net	1	1	(2)
Net cash used in investing activities	(4,701)	(1,455)	(2,857)
Financing activities
Proceeds and payments on short-term borrowings, net	(6)	(7)	(1)
Proceeds from issuance of long-term debt	3,292	2,642	3,126
Payments on long-term debt	(2,297)	(1,342)	(669)
Dividends paid	(863)	(778)	(703)
Repurchases of common stock	0	(307)	(300)
Cash paid for taxes from withheld shares	(110)	(136)	(120)
Payments to purchase noncontrolling interest	0	0	(14)
Other financing, net	(27)	(69)	10
Net cash provided by (used in) financing activities	(11)	3	1,329
Effect of exchange rate changes on cash and cash equivalents	41	(18)	(8)
Change in cash and cash equivalents	(1,394)	721	1,074
Cash and cash equivalents at beginning of year	4,337	3,616	2,542
Cash and cash equivalents at end of year	2,943	4,337	3,616
Supplemental cash flow disclosure:
Cash paid for income taxes, net of refunds	323	457	539
Cash paid for interest on debt	$ 304	$ 286	$ 248

Contingencies and Commitments

Contingencies and Commitments	12 Months Ended
	Dec. 31, 2020
Commitments and Contingencies Disclosure [Abstract]
Contingencies and Commitments	CONTINGENCIES AND COMMITMENTS We are involved in various ongoing proceedings, legal actions and claims arising in the normal course of business, including proceedings related to product, labor, intellectual property and other matters, the most significant of which are more fully described below. The outcomes of these matters will generally not be known for prolonged periods of time. In certain of the legal proceedings, the claimants seek damages as well as other compensatory and equitable relief that could result in the payment of significant claims and settlements and/or the imposition of injunctions or other equitable relief. For legal matters for which management had sufficient information to reasonably estimate our future obligations, a liability representing management's best estimate of the probable loss, or the minimum of the range of probable losses when a best estimate within the range is not known, is recorded. The estimates are based on consultation with legal counsel, previous settlement experience and settlement strategies. If actual outcomes are less favorable than those estimated by management, additional expense may be incurred, which could unfavorably affect future operating results. We are self-insured for certain claims and expenses. The ultimate cost to us with respect to product liability claims could be materially different than the amount of the current estimates and accruals and could have a material adverse effect on our financial position, results of operations and cash flows. Recall Matters In June 2012 we voluntarily recalled our Rejuvenate and ABG II Modular-Neck hip stems and terminated global distribution of these hip products. Product liability lawsuits relating to this voluntary recall have been filed against us. In November 2014 we entered into a settlement agreement to compensate eligible United States patients who had revision surgery prior to November 3, 2014 and in December 2016 the settlement program was extended to patients who had revision surgery prior to December 19, 2016. In September 2020 we entered into a second settlement agreement to compensate eligible United States patients who had revision surgery prior to September 9, 2020. We continue to offer support for recall-related care and reimburse patients who are not eligible to enroll in the settlement program for testing and treatment services, including any necessary revision surgeries. In addition, there are remaining lawsuits that we will continue to defend against. In August 2016 and May 2018 we voluntarily recalled certain lot-specific sizes and offsets of LFIT Anatomic CoCr V40 Femoral Heads. Product liability lawsuits and claims relating to this voluntary recall have been filed against us. In November 2018 we entered into a settlement agreement to resolve a significant number of claims and lawsuits related to the recalls. The specific terms of the settlement agreement, including the financial terms, are confidential. With the acquisition of Wright as more fully described in Note 6, we are responsible for certain product liability claims, primarily related to certain hip products sold by Wright prior to its 2014 divestiture of the OrthoRecon business. We will continue to evaluate each claim and the possible loss we may incur. We have incurred, and expect to incur in the future, costs associated with the defense and settlement of these matters. Based on the information that has been received, we have estimated the remaining range of probable loss related to these matters globally to be approximately $470 to $720. We have recorded reserves representing the remaining minimum of the range of probable loss. The final outcomes of these matters are dependent on many factors that are difficult to predict. Accordingly, the ultimate cost related to these matters may be materially different than the amount of our current estimate and accruals and could have a material adverse effect on our results of operations and cash flows. Leases We lease various manufacturing, warehousing and distribution facilities, administrative and sales offices as well as equipment under operating leases. We evaluate our contracts to identify leases, which is generally if there is an identified asset and we have the right to direct the use of and obtain substantially all of the economic benefit from the use of the identified asset. Certain of our lease agreements contain rent escalation clauses (including index-based escalations), rent holidays, capital improvement funding or other lease incentives. We recognize our minimum rental expense on a straight-line basis over the term of the lease beginning with the date of initial control of the asset. Right-of-use assets are recorded in Other noncurrent assets on our Consolidated Balance Sheets. Current and non-current lease liabilities are recorded in Accrued expenses and other liabilities and Other noncurrent liabilities, respectively. We have made certain significant assumptions and judgments when recording leases. For all asset classes, we elected to not recognize a right-of-use asset and lease liability for short-term leases and not separate non-lease components from lease components to which they relate and have accounted for the combined lease and non-lease components as a single lease component. The determination of the discount rate used in a lease is our incremental borrowing rate which is based on what we would normally pay to borrow on a collateralized basis over a similar term an amount equal to the lease payments. 2020 2019 Right-of-use assets $ 423 $ 384 Lease liabilities, current $ 109 $ 86 Lease liabilities, non-current $ 325 $ 301 Other information: Weighted-average remaining lease term 5.6 years 6.2 years Weighted-average discount rate 2.57 % 3.34 % Operating lease expense totaled $130, $133, and $138 in 2020, 2019 and 2018. Future Obligations We have purchase commitments for materials, supplies, services and property, plant and equipment as part of the normal course of business. In addition, we lease various manufacturing, warehousing and distribution facilities, administrative and sales offices as well as equipment under operating leases. Refer to Note 10 for more information on the debt obligations. 2021 2022 2023 2024 2025 Thereafter Debt repayments $ 761 $ 2 $ 1,670 $ 1,636 $ 1,400 $ 8,646 Purchase obligations $ 1,294 $ 76 $ 58 $ 52 $ 52 $ 55 Minimum lease payments $ 110 $ 87 $ 65 $ 38 $ 30 $ 90

Segment and Geographic Data

Segment and Geographic Data	12 Months Ended
	Dec. 31, 2020
Segment Reporting [Abstract]
Segment and Geographic Data	SEGMENT AND GEOGRAPHIC DATA We segregate our operations into three reportable business segments: Orthopaedics, MedSurg, and Neurotechnology and Spine. The Corporate and Other category shown in the table below includes corporate and administration, corporate initiatives and share-based compensation, which includes compensation related to employee stock options, restricted stock units and performance stock unit grants and director stock options and restricted stock unit grants. Segment Results 2020 2019 2018 Orthopaedics $ 4,959 $ 5,252 $ 4,991 MedSurg $ 6,400 6,492 6,045 Neurotechnology & Spine 2,992 3,140 2,565 Net sales $ 14,351 $ 14,884 $ 13,601 Orthopaedics $ 344 $ 348 $ 350 MedSurg 362 379 285 Neurotechnology & Spine 248 218 176 Segment depreciation and amortization $ 954 $ 945 $ 811 Corporate and Other 122 99 155 Total depreciation and amortization $ 1,076 $ 1,044 $ 966 Orthopaedics $ 1,518 $ 1,907 $ 1,804 MedSurg 1,837 1,642 1,444 Neurotechnology & Spine 647 839 700 Segment operating income $ 4,002 $ 4,388 $ 3,948 Items not allocated to segments: Corporate and Other $ (503) $ (480) $ (431) Acquisition and integration-related charges (242) (275) (123) Amortization of intangible assets (472) (464) (417) Restructuring-related and other charges (458) (226) (220) Medical device regulations (81) (62) (12) Recall-related matters (17) (192) (23) Regulatory and legal matters (6) 24 (185) Consolidated operating income $ 2,223 $ 2,713 $ 2,537 Segment Assets and Capital Spending Assets: 2020 2019 2018 Orthopaedics $ 14,910 $ 9,085 $ 8,873 MedSurg 17,901 12,066 10,417 Neurotechnology & Spine 529 7,646 7,260 Total segment assets $ 33,340 $ 28,797 $ 26,550 Corporate and Other 990 1,370 679 Total assets $ 34,330 $ 30,167 $ 27,229 Capital spending: Orthopaedics $ 140 $ 125 $ 134 MedSurg 174 265 217 Neurotechnology & Spine 28 29 31 Total segment capital spending $ 342 $ 419 $ 382 Corporate and Other 145 230 190 Total capital spending $ 487 $ 649 $ 572 We measure the financial results of our reportable segments using an internal performance measure that excludes acquisition and integration-related charges, restructuring-related charges, reserves for certain product recall matters and reserves for certain legal and regulatory matters. Identifiable assets are those assets used exclusively in the operations of each business segment or allocated when used jointly. Corporate assets are principally cash and cash equivalents, marketable securities and property, plant and equipment. The countries in which we have local revenue generating operations have been combined into the following geographic areas: the United States (including Puerto Rico); Europe, Middle East, Africa; Asia Pacific; and other foreign countries, which include Canada and countries in the Latin American region. Net sales are reported based on the geographic area of the Stryker location where the sales to the customer originated. Geographic Information Net Sales Net Property, Plant and Equipment 2020 2019 2018 2020 2019 United States $ 10,455 $ 10,957 $ 9,848 $ 1,645 $ 1,561 Europe, Middle East, Africa 1,818 1,888 1,793 938 838 Asia Pacific 1,630 1,617 1,532 91 95 Other countries 448 422 428 78 73 Total $ 14,351 $ 14,884 $ 13,601 $ 2,752 $ 2,567

Significant Accounting Policies

Significant Accounting Policies	12 Months Ended
	Dec. 31, 2020
Significant Accounting Policies [Abstract]
Significant Accounting Policies	SIGNIFICANT ACCOUNTING POLICIES Nature of Operations: Stryker (the "Company," "we," "us," or "our") is one of the world's leading medical technology companies and, together with its customers, is driven to make healthcare better. The Company offers innovative products and services in Orthopaedics, Medical and Surgical, and Neurotechnology and Spine that improve patient and hospital outcomes. Our products include implants used in joint replacement and trauma surgeries; surgical equipment and surgical navigation systems; endoscopic and communications systems; patient handling, emergency medical equipment and intensive care disposable products; neurosurgical, neurovascular and spinal devices; as well as other products used in a variety of medical specialties. Basis of Presentation and Consolidation: The Consolidated Financial Statements include the Company and its subsidiaries. All significant intercompany accounts and transactions are eliminated in consolidation. We have no material interests in variable interest entities and none that require consolidation. Certain prior year amounts have been reclassified to conform with current year presentation in our Consolidated Financial Statements, including immaterial reclassifications of segment results and $302 of loaner instrumentation not intended to be sold reclassified from inventories to other noncurrent assets. Use of Estimates: The preparation of financial statements in conformity with accounting principles generally accepted in the United States (GAAP) requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities on the date of the financial statements and the reported amounts of net sales and expenses in the reporting period. Actual results could differ from those estimates. Revenue Recognition: Sales are recognized as the performance obligations to deliver products or services are satisfied and are recorded based on the amount of consideration we expect to receive in exchange for satisfying the performance obligations. Our sales are recognized primarily when we transfer control to the customer, which can be on the date of shipment, the date of receipt by the customer or, for most Orthopaedics products, when we have received a purchase order and appropriate notification the product has been used or implanted. Products and services are primarily transferred to customers at a point in time, with some transfers of services taking place over time. Sales represent the amount of consideration we expect to receive from customers in exchange for transferring products and services. Net sales exclude sales, value added and other taxes we collect from customers. Other costs to obtain and fulfill contracts are generally expensed as incurred due to the short-term nature of most of our sales. We extend terms of payment to our customers based on commercially reasonable terms for the markets of our customers, while also considering their credit quality. A provision for estimated sales returns, discounts and rebates is recognized as a reduction of sales in the same period that the sales are recognized. Our estimate of the provision for sales returns has been established based on contract terms with our customers and historical business practices and current trends. Shipping and handling costs charged to customers are included in net sales. Cost of Sales: Cost of sales is primarily comprised of direct materials and supplies consumed in the manufacture of product, as well as manufacturing labor, depreciation expense and direct overhead expense necessary to acquire and convert the purchased materials and supplies into finished product. Cost of sales also includes the cost to distribute products to customers, inbound freight costs, warehousing costs and other shipping and handling activity. Research, Development and Engineering Expenses: Research and development costs are charged to expense as incurred. Costs include research, development and engineering activities relating to the development of new products, improvement of existing products, technical support of products and compliance with governmental regulations for the protection of customers and patients. Costs primarily consist of salaries, wages, consulting and depreciation and maintenance of research facilities and equipment. Selling, General and Administrative Expenses: Selling, general and administrative expense is primarily comprised of selling expenses, marketing expenses, administrative and other indirect overhead costs, amortization of loaner instrumentation, depreciation and amortization expense of non-manufacturing assets and other miscellaneous operating items. Currency Translation: Financial statements of subsidiaries outside the United States generally are measured using the local currency as the functional currency. Adjustments to translate those statements into United States Dollars are recorded in other comprehensive income (OCI). Transactional exchange gains and losses are included in other income (expense), net. Cash Equivalents: Highly liquid investments with remaining stated maturities of three months or less when purchased or other money market instruments that are redeemable upon demand are considered cash equivalents and recorded at cost. Marketable Securities: Marketable securities consist of marketable debt securities, certificates of deposit and mutual funds. Mutual funds are acquired to offset changes in certain liabilities related to deferred compensation arrangements and are expected to be used to settle these liabilities and are recorded in other noncurrent assets. Pursuant to our investment policy, all individual marketable security investments must have a minimum credit quality of single A (Standard & Poor’s and Fitch) and A2 (Moody’s Corporation) at the time of acquisition, while the overall portfolio of marketable securities must maintain a minimum average credit quality of double A (Standard & Poor’s and Fitch) or Aa (Moody’s Corporation). In the event of a rating downgrade below the minimum credit quality subsequent to purchase, the marketable security investment is evaluated to determine the appropriate action to take to minimize the overall risk to our marketable security investment portfolio. Our marketable securities are classified as available-for-sale and trading securities. Investments in trading securities represent participant-directed investments of deferred employee compensation. Accounts Receivable: Accounts receivable consists of trade and other miscellaneous receivables. An allowance is maintained for doubtful accounts for estimated losses in the collection of accounts receivable. Estimates are made regarding the ability of customers to make required payments based on historical credit experience, current market conditions and expected credit losses. Accounts receivable are written off when all reasonable collection efforts are exhausted. Inventories: Inventories are stated at the lower of cost or net realizable value, with cost generally determined using the first-in, first-out (FIFO) cost method. For excess and obsolete inventory resulting from the potential inability to sell specific products at prices in excess of current carrying costs, reserves are maintained to reduce current carrying cost to net realizable value. Financial Instruments: Our financial instruments consist of cash, cash equivalents, marketable securities, accounts receivable, other investments, accounts payable, debt and foreign currency exchange contracts. The carrying value of our financial instruments, with the exception of our senior unsecured notes, approximates fair value on December 31, 2020 and 2019. Refer to Notes 3 and 10 for further details. All marketable securities are recognized at fair value. Adjustments to the fair value of marketable securities that are classified as available-for-sale are recorded as increases or decreases, net of income taxes, within accumulated other comprehensive income (AOCI) in shareholders’ equity and adjustments to the fair value of marketable securities that are classified as trading are recorded in earnings. The amortized cost of marketable debt securities is adjusted for amortization of premiums and discounts to maturity computed under the effective interest method. Such amortization and interest and realized gains and losses are included in other income (expense), net. The cost of securities sold is determined by the specific identification method. We review declines in the fair value of our investments classified as available-for-sale to determine whether the decline in fair value is a result of credit loss or other factors. Impairments of available-for-sale marketable debt securities related to credit loss are included in earnings and impairments related to other factors are recognized within AOCI. Derivatives: All derivatives are recognized at fair value and reported on a gross basis. We enter into forward currency exchange contracts to mitigate the impact of currency fluctuations on transactions denominated in nonfunctional currencies, thereby limiting our risk that would otherwise result from changes in exchange rates. The periods of the forward currency exchange contracts correspond to the periods of the exposed transactions, with realized gains and losses included in the measurement and recording of transactions denominated in the nonfunctional currencies. All forward currency exchange contracts are recorded at their fair value each period. Forward currency exchange contracts designated as cash flow hedges are designed to hedge the variability of cash flows associated with forecasted transactions denominated in a foreign currency that will take place in the future. These nonfunctional currency exposures principally relate to forecasted intercompany sales and purchases of manufactured products and generally have maturities up to eighteen months. Changes in value of derivatives designated as cash flow hedges are recorded in AOCI on the Consolidated Balance Sheets until earnings are affected by the variability of the underlying cash flows. At that time, the applicable amount of gain or loss from the derivative instrument that is deferred in shareholders’ equity is reclassified into earnings and is included in cost of goods sold in the Consolidated Statements of Earnings. Cash flows associated with these hedges are included in cash from operations in the same category as the cash flows from the items being hedged. Forward currency exchange contracts are used to offset our exposure to the change in value of specific foreign currency denominated assets and liabilities, primarily intercompany payables and receivables. These derivatives are not designated as hedges and, therefore, changes in the value of these forward contracts are recognized in earnings, thereby offsetting the current earnings effect of the related changes in value of foreign currency denominated assets and liabilities. The estimated fair value of our forward currency exchange contracts represents the measurement of the contracts at month-end spot rates as adjusted by current forward points. From time to time, we designate derivative and non-derivative financial instruments as net investment hedges of our investments in certain international subsidiaries. For derivative instruments that are designated and qualify as a net investment hedge, the effective portion of the derivative's gain or loss is recognized in OCI and reported as a component of AOCI. We have elected to use the spot method to assess effectiveness for our derivatives designated as net investment hedges. Accordingly, the change in fair value attributable to changes in the spot rate is recorded in AOCI. We exclude the spot-forward difference from the assessment of hedge effectiveness and amortize this amount separately on a straight-line basis over the term of the forward contracts. This amortization is recognized in Other income (expense). From time to time, we designate forward starting interest rate derivative instruments as cash flow hedges to manage the exposure to interest rate volatility with regard to future issuance and refinancing of debt. Changes in value of derivatives designated as cash flow hedges are recorded in AOCI on the Consolidated Balance Sheets until earnings are affected by the variability of the underlying cash flows. At that time, the applicable amount of gain or loss from the derivative instrument that is deferred in shareholders’ equity is reclassified into earnings and is included in interest expense in the Consolidated Statements of Earnings. Interest rate derivative instruments designated as fair value hedges have been used in the past to manage the exposure to interest rate movements and to reduce borrowing costs by converting fixed-rate debt into floating-rate debt. Under these agreements, we agree to exchange, at specified intervals, the difference between fixed and floating interest amounts calculated by reference to an agreed-upon notional principal amount. Property, Plant and Equipment: Property, plant and equipment is stated at cost. Depreciation is generally computed by the straight-line method over the estimated useful lives of three three Goodwill and Other Intangible Assets: Goodwill represents the excess of purchase price over fair value of tangible net assets of acquired businesses at the acquisition date, after amounts allocated to other identifiable intangible assets. Factors that contribute to the recognition of goodwill include synergies that are specific to our business and not available to other market participants and are expected to increase net sales and profits; acquisition of a talented workforce; cost savings opportunities; the strategic benefit of expanding our presence in core and adjacent markets; and diversifying our product portfolio. The fair values of other identifiable intangible assets acquired in a business combination are primarily determined using the income approach. Other intangible assets include, but are not limited to, developed technology, customer and distributor relationships (which reflect expected continued customer or distributor patronage) and trademarks and patents. Intangible assets with determinable useful lives are amortized on a straight-line basis over their estimated useful lives of four In some of our acquisitions, we acquire in-process research and development (IPRD) intangible assets. For acquisitions accounted for as business combinations IPRD is considered to be an indefinite-lived intangible asset until the research is completed (then it becomes a determinable-lived intangible asset) or determined to have no future use (then it is impaired). For asset acquisitions IPRD is expensed immediately unless there is an alternative future use. Goodwill, Intangibles and Long-Lived Asset Impairment Tests: We perform our annual impairment test for goodwill in the fourth quarter of each year. We consider qualitative indicators of the fair value of a reporting unit when it is unlikely that a reporting unit has impaired goodwill. In certain circumstances, we may also utilize a discounted cash flow analysis that requires certain assumptions and estimates be made regarding market conditions and our future profitability. Indefinite-lived intangible assets are also tested at least annually for impairment by comparing the individual carrying values to the fair value. We review long-lived assets for indicators of impairment whenever events or changes in circumstances indicate that the carrying amount may not be recoverable. The evaluation is performed at the lowest level of identifiable cash flows. Undiscounted cash flows expected to be generated by the related assets are estimated over the asset's useful life based on updated projections. If the evaluation indicates that the carrying amount of the asset may not be recoverable, any potential impairment is measured based upon the fair value of the related asset or asset group as determined by an appropriate market appraisal or other valuation technique. Assets classified as held for sale are recorded at the lower of carrying amount or fair value less costs to sell. Share-Based Compensation: Share-based compensation is in the form of stock options, restricted stock units (RSUs) and performance stock units (PSUs). Stock options are granted under long-term incentive plans to certain key employees and non-employee directors at an exercise price not less than the fair market value of the underlying common stock, which is the quoted closing price of our common stock on the day prior to the date of grant. The options are granted for periods of up to 10 years and become exercisable in varying installments. We grant RSUs to key employees and non-employee directors and PSUs to certain key employees under our long-term incentive plans. The fair value of RSUs is determined based on the number of shares granted and the quoted closing price of our common stock on the date of grant, adjusted for the fact that RSUs do not include anticipated dividends. RSUs generally vest in one-third increments over a three-year period and are settled in stock. PSUs are earned over a three-year performance cycle and vest in March of the year following the end of that performance cycle. The number of PSUs that will ultimately be earned is based on our performance relative to pre-established goals in that three-year performance cycle. The fair value of PSUs is determined based on the quoted closing price of our common stock on the day of grant. Compensation expense is recognized in the Consolidated Statements of Earnings based on the estimated fair value of the awards on the grant date. Compensation expense recognized reflects an estimate of the number of awards expected to vest after taking into consideration an estimate of award forfeitures based on actual experience and is recognized on a straight-line basis over the requisite service period, which is generally the period required to obtain full vesting. Management expectations related to the achievement of performance goals associated with PSU grants is assessed regularly and that assessment is used to determine whether PSU grants are expected to vest. If performance-based milestones related to PSU grants are not met or not expected to be met, any compensation expense recognized associated with such grants will be reversed. Income Taxes: Deferred income tax assets and liabilities are determined based on differences between financial reporting and income tax bases of assets and liabilities and are measured using the enacted income tax rates in effect for the years in which the differences are expected to reverse. Deferred income tax benefits generally represent the change in net deferred income tax assets and liabilities in the year. Other amounts result from adjustments related to acquisitions and foreign currency as appropriate. We operate in multiple income tax jurisdictions both within the United States and internationally. Accordingly, management must determine the appropriate allocation of income to each of these jurisdictions based on current interpretations of complex income tax regulations. Income tax authorities in these jurisdictions regularly perform audits of our income tax filings. Income tax audits associated with the allocation of this income and other complex issues, including inventory transfer pricing and cost sharing, product royalty and foreign branch arrangements, may require an extended period of time to resolve and may result in significant income tax adjustments if changes to the income allocation are required between jurisdictions with different income tax rates. New Accounting Pronouncements Not Yet Adopted We evaluate all Accounting Standards Updates (ASUs) issued by the Financial Accounting Standards Board (FASB) for consideration of their applicability. ASUs not included in our disclosures were assessed and determined to be either not applicable or are not expected to have a material impact on our Consolidated Financial Statements. Accounting Pronouncements Recently Adopted On January 1, 2020 we adopted ASU 2016-13, Financial Instruments - Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments . The standard replaces the incurred loss impairment methodology with a methodology that reflects expected credit losses for accounts receivables and loans. The adoption of this update did not have a material impact on our Consolidated Financial Statements. No other new accounting pronouncements were issued or became effective in the period that had, or are expected to have, a material impact on our Consolidated Financial Statements.
Financial Instruments	Our financial instruments consist of cash, cash equivalents, marketable securities, accounts receivable, other investments, accounts payable, debt and foreign currency exchange contracts. The carrying value of our financial instruments, with the exception of our senior unsecured notes, approximates fair value on December 31, 2020 and 2019. Refer to Notes 3 and 10 for further details. All marketable securities are recognized at fair value. Adjustments to the fair value of marketable securities that are classified as available-for-sale are recorded as increases or decreases, net of income taxes, within accumulated other comprehensive income (AOCI) in shareholders’ equity and adjustments to the fair value of marketable securities that are classified as trading are recorded in earnings. The amortized cost of marketable debt securities is adjusted for amortization of premiums and discounts to maturity computed under the effective interest method. Such amortization and interest and realized gains and losses are included in other income (expense), net. The cost of securities sold is determined by the specific identification method. We review declines in the fair value of our investments classified as available-for-sale to determine whether the decline in fair value is a result of credit loss or other factors. Impairments of available-for-sale marketable debt securities related to credit loss are included in earnings and impairments related to other factors are recognized within AOCI.

Revenue Recognition

Revenue Recognition	12 Months Ended
	Dec. 31, 2020
Revenue Recognition [Abstract]
Revenue Recognition	REVENUE RECOGNITION We disaggregate our net sales by product line and geographic location for each of our segments as we believe it best depicts how the nature, amount, timing and certainty of our net sales and cash flows are affected by economic factors. Products and services are primarily transferred to customers at a point in time, with some transfers of services taking place over time. In 2020 less than 10% of our sales were recognized as services transferred over time. Refer to Note 1 for further discussion on our revenue recognition policies. Segment Net Sales Orthopaedics: 2020 2019 2018 Knees $ 1,567 $ 1,815 $ 1,701 Hips 1,206 1,383 1,336 Trauma and Extremities 1,722 1,639 1,580 Other 464 415 374 $ 4,959 $ 5,252 $ 4,991 MedSurg: Instruments $ 1,863 $ 1,959 $ 1,822 Endoscopy 1,763 1,983 1,846 Medical 2,524 2,264 2,118 Sustainability 250 286 259 $ 6,400 $ 6,492 $ 6,045 Neurotechnology and Spine: Neurotechnology $ 1,945 $ 1,983 $ 1,737 Spine 1,047 1,157 828 $ 2,992 $ 3,140 $ 2,565 Total $ 14,351 $ 14,884 $ 13,601 United States Net Sales Orthopaedics: 2020 2019 2018 Knees $ 1,170 $ 1,347 $ 1,244 Hips 777 882 838 Trauma and Extremities 1,139 1,051 1,001 Other 387 334 300 $ 3,473 $ 3,614 $ 3,383 MedSurg: Instruments $ 1,471 $ 1,542 $ 1,424 Endoscopy 1,408 1,577 1,432 Medical 1,910 1,787 1,630 Sustainability 247 283 257 $ 5,036 $ 5,189 $ 4,743 Neurotechnology and Spine: Neurotechnology $ 1,182 $ 1,281 $ 1,115 Spine 764 873 607 $ 1,946 $ 2,154 $ 1,722 Total $ 10,455 $ 10,957 $ 9,848 International Net Sales Orthopaedics: 2020 2019 2018 Knees $ 397 $ 469 $ 457 Hips 429 500 498 Trauma and Extremities 583 588 579 Other 77 81 74 $ 1,486 $ 1,638 $ 1,608 MedSurg: Instruments $ 392 $ 417 $ 398 Endoscopy 355 406 414 Medical 614 477 488 Sustainability 3 3 2 $ 1,364 $ 1,303 $ 1,302 Neurotechnology and Spine: Neurotechnology $ 763 $ 702 $ 622 Spine 283 284 221 $ 1,046 $ 986 $ 843 Total $ 3,896 $ 3,927 $ 3,753 Orthopaedics Orthopaedics products consist primarily of implants used in hip and knee joint replacements and trauma and extremity surgeries. Substantially all Orthopaedics sales are recognized when we have received a purchase order and appropriate notification the product has been used or implanted. For certain Orthopaedic products in the "other" category, we recognize sales at a point in time, as well as over time for performance obligations that may include an obligation to complete installation, provide training and ongoing services. Performance obligations are satisfied within one year. MedSurg MedSurg products include surgical equipment and navigation systems (Instruments), endoscopic and communications systems (Endoscopy), patient handling, emergency medical equipment and intensive care disposable products (Medical), reprocessed and remanufactured medical devices (Sustainability) and other medical device products used in a variety of medical specialties. Substantially all MedSurg sales are recognized when a purchase order has been received and control has transferred. For certain Endoscopy, Instruments and Medical services, we may recognize sales over time as we satisfy performance obligations that may include an obligation to complete installation, provide training and perform ongoing services, generally performed within one year. Neurotechnology and Spine Neurotechnology and Spine products include neurosurgical, neurovascular, and spinal implant devices. Our neurotechnology offering includes products used for minimally invasive endovascular techniques; a comprehensive line of products for traditional brain and open skull based surgical procedures; orthobiologic and biosurgery products, including synthetic bone grafts and vertebral augmentation products; and minimally invasive products for the treatment of acute ischemic and hemorrhagic stroke. Our spinal implant offering includes cervical, thoracolumbar and interbody systems used in spinal injury, deformity and degenerative therapies. Substantially all Neurotechnology and Spine sales are recognized when a purchase order has been received and control has transferred. Contract Assets and Liabilities The nature of our products and services do not generally give rise to contract assets as we typically do not incur costs to fulfill a contract before a product or service is provided to a customer. Our costs to obtain contracts are typically in the form of sales commissions paid to employees or third-party agents. Certain sales commissions paid to employees prior to recognition of sales are recorded as contract assets. We expense sales commissions associated with obtaining a contract at the time of the sale or as incurred as the amortization period is generally less than one year. These costs have been presented within selling, general and administrative expenses. On December 31, 2020 contract assets recorded in our Consolidated Balance Sheets were not significant.

Fair Value Measurements

Fair Value Measurements	12 Months Ended
	Dec. 31, 2020
Fair Value Disclosures [Abstract]
Fair Value Measurements	FAIR VALUE MEASUREMENTS Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. Financial assets and liabilities carried at fair value are classified in their entirety based on the lowest level of input and disclosed in one of the following three categories: Level 1 Quoted market prices in active markets for identical assets or liabilities. Level 2 Observable market-based inputs or unobservable inputs that are corroborated by market data. Level 3 Unobservable inputs reflecting our assumptions or external inputs from active markets. Use of observable market data, when available, is required in making fair value measurements. When inputs used fall within different levels of the hierarchy, the level within which the fair value measurement is categorized is based on the lowest level input that is significant to the fair value measurement. We determine fair value for Level 1 instruments using exchange-traded prices for identical instruments. We determine fair value of Level 2 instruments using exchange-traded prices of similar instruments, where available, or utilizing other observable inputs that take into account our credit risk and that of our counterparties. Foreign currency exchange contracts and interest rate hedges are included in Level 2 and we use inputs other than quoted prices that are observable for the asset or liability. The Level 2 derivative instruments are primarily valued using standard calculations and models that use readily observable market data as their basis. Our Level 3 liabilities are comprised of contingent consideration arising from recently completed acquisitions. We determine fair value of these Level 3 liabilities using a discounted cash flow technique. Significant unobservable inputs were used in our assessment of fair value, including assumptions regarding future business results, discount rates, discount periods and probability assessments based on the likelihood of reaching various targets. We remeasure the fair value of our assets and liabilities each reporting period. We record the changes in fair value within selling, general and administrative expense and the changes in the time value of money within other income (expense), net. Assets Measured at Fair Value 2020 2019 Cash and cash equivalents $ 2,943 $ 4,337 Trading marketable securities 171 149 Level 1 - Assets $ 3,114 $ 4,486 Available-for-sale marketable securities: Corporate and asset-backed debt securities $ 38 $ 32 United States agency debt securities 5 2 United States treasury debt securities 36 49 Certificates of deposit 2 5 Total available-for-sale marketable securities $ 81 $ 88 Foreign currency exchange forward contracts 20 226 Interest rate swap asset — 17 Level 2 - Assets $ 101 $ 331 Total assets measured at fair value $ 3,215 $ 4,817 Liabilities Measured at Fair Value 2020 2019 Deferred compensation arrangements $ 171 $ 149 Level 1 - Liabilities $ 171 $ 149 Foreign currency exchange forward contracts $ 160 $ 23 Interest rate swap liability 53 — Level 2 - Liabilities $ 213 $ 23 Contingent consideration: Beginning $ 306 $ 117 Additions 108 298 Change in estimate 9 (10) Settlements (30) (99) Ending $ 393 $ 306 Level 3 - Liabilities $ 393 $ 306 Total liabilities measured at fair value $ 777 $ 478 Fair Value of Available for Sale Securities by Maturity 2020 2019 Due in one year or less $ 42 $ 50 Due after one year through three years $ 39 $ 38 On December 31, 2020 the aggregate difference between the cost and fair value of available-for-sale marketable securities was nominal. Interest and marketable securities income was $102, $155 and $119 in 2020, 2019 and 2018, which was recorded in other income (expense), net. Our investments in available-for-sale marketable securities had a minimum credit quality rating of A2 (Moody's), A (Standard & Poor's) and A (Fitch). We do not plan to sell the investments, and it is not more likely than not that we will be required to sell the investments before recovery of their amortized cost basis, which may be maturity.

Derivative Instruments

Derivative Instruments	12 Months Ended
	Dec. 31, 2020
Derivative Instruments and Hedging Activities Disclosure [Abstract]
Derivative Instruments	DERIVATIVE INSTRUMENTS We use operational and economic hedges, foreign currency exchange forward contracts, net investment hedges (both derivative and non-derivative financial instruments) and interest rate derivative instruments to manage the impact of currency exchange and interest rate fluctuations on earnings, cash flow and equity. We do not enter into derivative instruments for speculative purposes. We are exposed to potential credit loss in the event of nonperformance by counterparties on our outstanding derivative instruments but do not anticipate nonperformance by any of our counterparties. Should a counterparty default, our maximum loss exposure is the asset balance of the instrument. Foreign Currency Hedges 2020 Cash Flow Net Investment Non-Designated Total Gross notional amount $ 949 $ 1,828 $ 5,382 $ 8,159 Maximum term in days 1793 Fair value: Other current assets $ 9 $ — $ 7 $ 16 Other noncurrent assets — 4 — 4 Other current liabilities (12) — (121) (133) Other noncurrent liabilities (1) (26) — (27) Total fair value $ (4) $ (22) $ (114) $ (140) 2019 Gross notional amount $ 801 $ 1,113 $ 6,174 $ 8,088 Maximum term in days 1646 Fair value: Other current assets $ 5 $ — $ 180 $ 185 Other noncurrent assets 1 40 — 41 Other current liabilities (10) — (11) (21) Other noncurrent liabilities (2) — — (2) Total fair value $ (6) $ 40 $ 169 $ 203 In December 2019 and November 2018 we designated the issuance of €2,400 and €2,250 of senior unsecured notes as net investment hedges to selectively hedge portions of our investment in certain international subsidiaries. In November 2020 a €300 debt maturity was paid off and de-designated as a net investment hedge. The currency effects of our Euro-denominated senior unsecured notes are reflected in AOCI within shareholders' equity where they offset gains and losses recorded on our net investment in international subsidiaries. In July 2019 and November 2020 we entered into €1.0 billion and €500 in certain forward currency contracts and designated these as net investment hedges to hedge a portion of our investments in certain of our entities with functional currencies denominated in Euros. On December 31, 2020 the total after-tax gain (loss) in AOCI related to designated net investment hedges was ($386). Net Currency Exchange Rate Gains (Losses) Derivative Instrument Recorded in: 2020 2019 2018 Cash Flow Cost of sales $ 5 $ 2 $ 7 Net Investment Other income (expense), net 28 14 — Non-Designated Other income (expense), net (13) (7) (6) Total $ 20 $ 9 $ 1 Pretax gains (losses) on derivatives designated as cash flow hedges of ($2) and net investment hedges of $33 recorded in AOCI are expected to be reclassified to cost of sales and other income (expense) in earnings within 12 months as of December 31, 2020. This cash flow hedge reclassification is primarily due to the sale of inventory that includes previously hedged purchases. A component of the AOCI amounts related to net investment hedges is reclassified over the life of the hedge instruments as we elected to exclude the initial value of the component related to the spot-forward difference from the effectiveness assessment. Interest Rate Hedges In conjunction with our offerings of senior unsecured notes in December 2019 and June 2020 we terminated certain interest rate derivative contracts with gross notional amounts of €600 and $500 designated as cash flow hedges, the impact of which will be recognized over the life of the underlying issued debt within interest expense. Pretax gains recorded in AOCI related to closed interest rate hedges of $6 are expected to be reclassified to other income (expense) in earnings within 12 months of December 31, 2020. On December 31, 2020 we had forward starting interest rate swap agreements with notional amounts of $750 designated as cash flow hedges in anticipation of future debt issuances. Pretax losses of $53 were recorded in AOCI as of December 31, 2020. Upon the probable issuance of the debt, these amounts will be released to interest expense over the term of the debt. The cash flow effect of these hedges is recorded in cash flow from operations.

Accumulated Other Comprehensive

Accumulated Other Comprehensive (Loss) Income (AOCI)	12 Months Ended
	Dec. 31, 2020
Reclassification Adjustments Out of Accumulated Other Comprehensive Income (AOCI) [Abstract]
Accumulated Other Comprehensive (Loss) Income (AOCI)	ACCUMULATED OTHER COMPREHENSIVE (LOSS) INCOME (AOCI) Marketable Securities Pension Plans Hedges Financial Statement Translation Total 2018 $ (4) $ (137) $ 50 $ (540) $ (631) OCI — (74) 3 101 30 Income taxes — 26 — (21) 5 Reclassifications to: Cost of Sales — — (2) — (2) Other (income) expense 1 8 (5) (14) (10) Income taxes — (2) 1 3 2 Net OCI 1 (42) (3) 69 25 2019 $ (3) $ (179) $ 47 $ (471) $ (606) OCI — (117) (64) (459) (640) Income taxes — 28 17 66 111 Reclassifications to: Cost of Sales — — (5) — (5) Other (income) expense — 12 (6) (28) (22) Income taxes — (3) 1 7 5 Net OCI — (80) (57) (414) (551) 2020 $ (3) $ (259) $ (10) $ (885) $ (1,157)

Acquisitions

Acquisitions	12 Months Ended
	Dec. 31, 2020
Business Combinations [Abstract]
Acquisitions	ACQUISITIONSWe acquire stock in companies and various assets that continue to support our capital deployment and product development strategies. The aggregate purchase price of our acquisitions, net of cash acquired was $4,304 and $1,096 in 2020 and 2019. In November 2020 we completed the acquisition of Wright Medical Group N.V. (Wright) for $30.75 per share, or an aggregate purchase price of $4.1 billion ($5.6 billion including convertible notes). Wright is a global medical device company focused on extremities and biologics. Wright is part of our Trauma and Extremities business within Orthopaedics. Goodwill attributable to the acquisition is not deductible for tax purposes . In November and December 2020 note holders elected to redeem the 1.625% and 2.25% convertible notes assumed in the Wright acquisition for $864 and $576. These repayments are classified as financing activities. In December 2020 we completed the acquisition of OrthoSensor, Inc. (OrthoSensor). OrthoSensor is a leader in the digital evolution of musculoskeletal care and sensor technology for total joint replacement. OrthoSensor is part of our Joint Replacement business within Orthopaedics. Goodwill attributable to the acquisition is not deductible for tax purposes . In October 2019 we completed the acquisition of Mobius Imaging and Cardan Robotics for net cash consideration of $360 and future regulatory and commercial milestone payments of up to $130. Mobius Imaging is a leader in point-of-care imaging technology focused on integrating advanced imaging technologies into medical workflow. Cardan Robotics is working to develop innovative robotics and navigation technology systems for surgical and interventional radiology procedures. Mobius Imaging and Cardan Robotics (Mobius) are part of our Spine business within Neurotechnology and Spine. For income tax purposes the acquisition is treated as an asset purchase. Goodwill attributable to the acquisition is deductible for tax purposes. In March 2019 we completed the acquisition of OrthoSpace, Ltd. (OrthoSpace) for net cash consideration of $110 and future regulatory milestone payments of up to $110. OrthoSpace is a medical device company specializing in orthopaedic biodegradable technology for the treatment of irreparable rotator cuff tears. OrthoSpace is part of our Endoscopy business within MedSurg. Goodwill attributable to the acquisition is not deductible for tax purposes. Had the above acquisitions taken place as of the beginning of the comparable prior year, our consolidated financial results of operations in the aggregate would not have been materially different. Accordingly, we have not disclosed pro forma financial information. Purchase price allocations for our significant acquisitions are: Purchase Price Allocation of Acquired Net Assets 2020 Wright Tangible assets acquired: Accounts receivable $ 127 Deferred income tax assets 371 Inventory 485 Other assets 344 Debt (1,447) Deferred income tax liabilities (511) Product liabilities (192) Other liabilities (288) Intangible assets: Customer and distributor relationships 181 Developed technology and patents 1,523 Trade name 60 Goodwill 3,428 Purchase price, net of cash acquired $ 4,081 Weighted average life of intangible assets 12 2019 Mobius OrthoSpace Tangible assets acquired: Accounts receivable $ 3 $ 1 Inventory 6 1 Other assets 2 1 Contingent consideration (4) — Other liabilities (10) (29) Intangible assets: Customer relationship 7 — Developed technology and patents 59 120 In-process research and development 98 — Non-compete agreements 9 — Goodwill 303 114 Purchase price, net of cash acquired $ 473 $ 208 Weighted average life of intangible assets 12 18

Goodwill and Other Intangible A

Goodwill and Other Intangible Assets	12 Months Ended
	Dec. 31, 2020
Goodwill and Intangible Assets Disclosure [Abstract]
Goodwill and Other Intangibles	GOODWILL AND OTHER INTANGIBLE ASSETS We completed our annual impairment tests of goodwill in 2020 and 2019 and concluded in each year that no impairments exist. Summary of Other Intangible Assets Weighted Average Amortization Period (Years) Gross Less Net Developed technologies 2020 13 $ 5,305 $ 1,573 $ 3,732 2019 14 3,731 1,271 2,460 Customer relationships 2020 15 $ 2,352 $ 988 $ 1,364 2019 16 2,160 848 1,312 Patents 2020 12 $ 346 $ 278 $ 68 2019 11 348 265 83 Trademarks 2020 17 $ 428 $ 162 $ 266 2019 18 362 136 226 In-process research and development 2020 N/A $ 97 $ — $ 97 2019 N/A 110 — 110 Other 2020 8 $ 128 $ 101 $ 27 2019 8 125 89 36 Total 2020 14 $ 8,656 $ 3,102 $ 5,554 2019 14 6,836 2,609 4,227 Changes in the Net Carrying Value of Goodwill by Segment Orthopaedics MedSurg Neurotechnology and Spine Total 2018 $ 2,399 $ 3,581 $ 2,583 $ 8,563 Additions and adjustments — 229 318 547 Foreign exchange (13) (11) (17) (41) 2019 $ 2,386 $ 3,799 $ 2,884 $ 9,069 Additions and adjustments 3,551 1 7 3,559 Foreign exchange 67 31 52 150 2020 $ 6,004 $ 3,831 $ 2,943 $ 12,778 Estimated Amortization Expense 2021 2022 2023 2024 2025 $ 600 $ 588 $ 567 $ 540 $ 518

Capital Stock

Capital Stock	12 Months Ended
	Dec. 31, 2020
Capital Stock [Abstract]
Capital Stock	CAPITAL STOCK The aggregate number of shares of all classes of stock with which we are authorized to issue is up to 1,000,500,000, divided into two classes consisting of 500,000 shares of $1 par value preferred stock and 1,000,000,000 shares of common stock with a par value of $0.10. No shares of preferred stock were outstanding on December 31, 2020. We made no repurchases of shares in 2020. The manner, timing and amount of repurchases are determined by management based on an evaluation of market conditions, stock price and other factors and are subject to regulatory considerations. Purchases are made from time-to-time in the open market, in privately negotiated transactions or otherwise. On December 31, 2020 the total dollar value of shares that could be purchased under our authorized repurchase program was $1,033. Shares reserved for future compensation grants of our common stock were 28 million and 31 million on December 31, 2020 and 2019. Stock Options We measure the cost of employee stock options based on the grant-date fair value and recognize that cost using the straight-line method over the period in which a recipient is required to provide services in exchange for the options, typically the vesting period. The weighted-average fair value per share of options is estimated on the date of grant using the Black-Scholes option pricing model. Option Value and Assumptions 2020 2019 2018 Weighted-average fair value per share $ 39.34 $ 36.30 $ 28.52 Assumptions: Risk-free interest rate 1.4 % 2.6 % 2.7 % Expected dividend yield 1.0 % 1.1 % 1.2 % Expected stock price volatility 18.9 % 18.3 % 16.8 % Expected option life (years) 5.8 5.9 6.0 The risk-free interest rate for periods within the expected life of options granted is based on the United States Treasury yield curve in effect at the time of grant. Expected stock price volatility is based on the historical volatility of our stock. The expected option life, representing the period of time that options granted are expected to be outstanding, is based on historical option exercise and employee termination data. 2020 Stock Option Activity Shares Weighted Weighted-Average Aggregate Outstanding January 1 12.8 $ 113.10 Granted 1.8 216.28 Exercised (2.0) 83.75 Canceled (0.4) 162.98 Outstanding December 31 12.2 $ 131.72 5.9 $ 1,388.1 Exercisable December 31 6.8 $ 99.09 4.4 $ 995.7 Options expected to vest 4.9 $ 171.06 7.7 $ 364.3 The aggregate intrinsic value of options, which represents the cumulative difference between the fair market value of the underlying common stock and the option exercise prices, exercised was $258, $294, and $247 in 2020, 2019 and 2018. Exercise prices for options outstanding ranged from $53.60 to $216.35 on December 31, 2020. On December 31, 2020 there was $99 of unrecognized compensation cost related to nonvested stock options granted under the long-term incentive plans; that cost is expected to be recognized over the weighted-average period of approximately 1.4 years. Restricted Stock Units (RSUs) and Performance Stock Units (PSUs) Activity Shares Weighted Average RSUs PSUs RSUs PSUs Nonvested on January 1 0.8 0.2 $ 158.80 $ 152.44 Granted 0.4 0.1 208.96 217.73 Vested (0.4) (0.1) 149.09 122.41 Canceled or forfeited — — 154.38 166.99 Nonvested on December 31 0.8 0.2 $ 187.72 $ 185.46 On December 31, 2020 there was $68 of unrecognized compensation cost related to nonvested RSUs. That cost is expected to be recognized as expense over the weighted-average period of approximately one year. The weighted-average grant date fair value per share of RSUs granted was $208.96 and $175.96 in 2020 and 2019. The fair value of RSUs and PSUs vested in 2020 was $55 and $9. On December 31, 2020 there was $16 of unrecognized compensation cost related to nonvested PSUs; the cost is expected to be recognized as expense over the weighted-average period of approximately one year. Employee Stock Purchase Plans (ESPP) Full- and part-time employees may participate in our ESPP provided they meet certain eligibility requirements. The purchase price for our common stock under the terms of the ESPP is defined as 95% of the closing stock price on the last trading day of a purchase period. We issued 209,837 and 166,758 shares under the ESPP in 2020 and 2019.

Debt and Credit Facilities

Debt and Credit Facilities	12 Months Ended
	Dec. 31, 2020
Long-term Debt, Unclassified [Abstract]
Debt And Credit Facilities	DEBT AND CREDIT FACILITIES We have lines of credit issued by various financial institutions that are available to fund our day-to-day operating needs. Certain of our credit facilities require us to comply with financial and other covenants. We were in compliance with all covenants on December 31, 2020. Our commercial paper program allows us to have a maximum of $1,500 in commercial paper outstanding with maturities up to 397 days from the date of issuance. On December 31, 2020 there were no amounts outstanding under our commercial paper program. Summary of Total Debt Senior unsecured notes: Rate Due 2020 2019 4.375% January 15, 2020 $ — $ 500 Variable November 30, 2020 — 333 2.625% March 15, 2021 750 749 1.125% November 30, 2023 668 609 0.600% December 1, 2023 597 — 3.375% May 15, 2024 590 587 0.250% December 3, 2024 1,030 938 1.150% June 15, 2025 644 — 3.375% November 1, 2025 747 746 3.500% March 15, 2026 992 991 2.125% November 30, 2027 909 829 3.650% March 7, 2028 596 596 0.750% March 1, 2029 969 884 1.950% June 15, 2030 989 — 2.625% November 30, 2030 782 712 1.000% December 3, 2031 903 823 4.100% April 1, 2043 392 391 4.375% May 15, 2044 395 395 4.625% March 15, 2046 981 981 2.900% June 15, 2050 641 — Term loan 400 — Other 16 26 Total debt $ 13,991 $ 11,090 Less current maturities 761 859 Total long-term debt $ 13,230 $ 10,231 Unamortized debt issuance costs $ 71 $ 58 Borrowing capacity on existing facilities $ 2,903 $ 1,546 Fair value of senior unsecured notes $ 15,022 $ 11,910 The fair value of the senior unsecured notes was estimated using quoted interest rates, maturities and amounts of borrowings based on quoted active market prices and yields that took into account the underlying terms of the debt instruments. Substantially all of our debt is classified within Level 2 of the fair value hierarchy. In January 2020 we repaid $500 of senior unsecured notes with a coupon of 4.375% that were due on January 15, 2020. On April 30, 2020 we amended our primary credit facility. The principal change was to increase the leverage ratio financial covenant from 3.5:1 to 4.5:1 at the end of each fiscal quarter ending on or prior to June 30, 2021. We exercised our right under the acquisition clause of the agreement to increase the maximum permitted leverage to 5.0:1 effective as of December 31, 2020. On April 30, 2020 we entered into a credit agreement that provides for up to $1,500 of borrowings in United States Dollars pursuant to a 364-day revolving credit facility, which matures on April 29, 2021 and is available for working capital and general corporate purposes. In June 2020 we issued $650 of senior unsecured notes with a fixed interest rate of 1.150% due on June 15, 2025, $1,000 of senior unsecured notes with a fixed interest rate of 1.950% due on June 15, 2030 and $650 of senior unsecured notes with a fixed interest rate of 2.900% due on June 15, 2050. In November 2020 we issued $600 of senior unsecured notes with a fixed interest rate of 0.600% due on December 1, 2023. In November 2020 we entered into a $400 term loan agreement that matures on November 10, 2023 and bears interest at LIBOR plus 112.5 bps. In November 2020 we repaid €300 of senior unsecured notes with a floating interest rate that were due on November 30, 2020. In November and December 2020 we settled the convertible notes assumed in the Wright acquisition. Refer to Note 6 for further information.

Income Taxes

Income Taxes	12 Months Ended
	Dec. 31, 2020
Income Tax Disclosure [Abstract]
Income Taxes	INCOME TAXES Our effective tax rate was 18.2%, 18.7% and (50.8%) for 2020, 2019 and 2018. The effective income tax rate for 2020 reflects the continued lower effective income tax rates as a result of our European operations, the tax effect related to the transfer of intellectual property between tax jurisdictions and the tax effect of future remittances of the undistributed earnings of foreign subsidiaries. The effective income tax rate for 2019 reflects the tax effect related to the transfer of intellectual properties between tax jurisdictions and the effective income tax rates as a result of our European operations. The effective income tax rate for 2018 reflects the tax effect related to the transfer of intellectual properties between tax jurisdictions, the continued impact of complying with the Tax Cuts and Jobs Act of 2017 (the Tax Act) and continued lower effective tax rates as a result of our European operations. Effective Income Tax Rate Reconciliation 2020 2019 2018 United States federal statutory rate 21.0 % 21.0 % 21.0 % United States state and local income taxes, less federal deduction 0.1 1.7 0.4 Foreign income tax at rates other than 21% (3.3) (4.6) (6.5) Tax Cuts and Jobs Act of 2017 transition tax — — 2.2 Tax Cuts and Jobs Act of 2017 deferred tax changes — — (0.6) Tax related to repatriation of foreign earnings 3.0 (0.5) 0.5 Intellectual property transfer (1.4) 3.5 (63.8) Other (1.2) (2.4) (4.0) Effective income tax rate 18.2 % 18.7 % (50.8) % In December 2017 the Tax Act was signed into law in the United States. The law includes significant changes to the United States corporate income tax system, including a federal corporate rate reduction, limitations on the deductibility of certain expenses and the transition of United States international taxation from a worldwide tax system to a territorial tax system. As part of the transition to a territorial tax system, the Tax Act required taxpayers to calculate a one-time transition tax based on undistributed earnings of foreign subsidiaries. The Tax Act subjects a United States shareholder to tax on Global Intangible Low-Taxed Income (GILTI) earned by certain foreign subsidiaries. We have elected to account for GILTI tax in the year the tax is incurred. Earnings Before Income Taxes 2020 2019 2018 United States $ 239 $ 366 $ 509 International 1,715 2,196 1,847 Total $ 1,954 $ 2,562 $ 2,356 Components of Income Tax Expense (Benefit) Current income tax expense: 2020 2019 2018 United States federal $ 80 $ (17) $ 178 United States state and local 20 46 30 International 207 324 177 Total current income tax expense $ 307 $ 353 $ 385 Deferred income tax (benefit) expense: United States federal $ 1 $ 10 $ (44) United States state and local (25) (1) (20) International 72 117 (1,518) Total deferred income tax (benefit) expense $ 48 $ 126 $ (1,582) Total income tax (benefit) expense $ 355 $ 479 $ (1,197) Interest and penalties included in other income (expense), net were expense of ($35), ($9) and ($9) in 2020, 2019 and 2018. The United States federal deferred income tax benefit (expense) includes the utilization of net operating loss carryforwards of $41, $50 and $31 in 2020, 2019 and 2018. Deferred Income Tax Assets and Liabilities Deferred income tax assets: 2020 2019 Inventories $ 434 $ 415 Product-related liabilities 48 57 Other accrued expenses 512 221 Depreciation and amortization 1,269 1,363 State income taxes 108 65 Share-based compensation 56 49 Net operating loss carryforwards 373 95 Other 263 207 Total deferred income tax assets $ 3,063 $ 2,472 Less valuation allowances (203) (75) Net deferred income tax assets $ 2,860 $ 2,397 Deferred Income Tax Assets and Liabilities Deferred income tax liabilities: 2020 2019 Depreciation and amortization $ (1,286) $ (893) Undistributed earnings (161) (37) Other — — Total deferred income tax liabilities $ (1,447) $ (930) Net deferred income tax assets $ 1,413 $ 1,467 Reported as: Noncurrent deferred income tax assets $ 1,530 $ 1,575 Noncurrent liabilities—Other liabilities (117) (108) Total $ 1,413 $ 1,467 Accrued interest and penalties were $133 and $94 on December 31, 2020 and 2019 which were reported in current and noncurrent accrued expenses and other liabilities. Net operating loss carryforwards totaling $1,642 with $410 being subject to a full valuation allowance ($1,409 and $405 related to the Wright acquisition) on December 31, 2020 are available to reduce future taxable earnings of certain domestic and foreign subsidiaries. United States loss carryforwards of $1,509 expire through 2045. International loss carryforwards of $132 begin to expire in 2022; however, some have no expiration. We also have tax credit carryforwards of $97 with $93 being subject to a full valuation allowance. The credits with a full valuation allowance begin to expire in 2025; however, some have no expiration. We do not anticipate generating income tax in excess of the non-expiring credits in the foreseeable future. We recorded a transition tax on undistributed foreign earnings as required by the Tax Act. No other provision was made for United States income taxes that may result from future remittances of the undistributed earnings of foreign subsidiaries that are determined to be indefinitely reinvested. We recorded deferred income tax on undistributed earnings of foreign subsidiaries not determined to be indefinitely reinvested. Determination of the total amount of unrecognized deferred income tax on undistributed earnings of foreign subsidiaries is not practicable. Uncertain Income Tax Positions 2020 2019 Beginning uncertain tax positions $ 472 $ 528 Increases related to current year income tax positions 12 62 Increases related to prior year income tax positions 5 5 Decreases related to prior year income tax positions: Settlements and resolutions of income tax audits (41) (78) Statute of limitations expirations and other (7) (40) Foreign currency translation 16 (5) Ending uncertain tax positions $ 457 $ 472 Reported as: Noncurrent liabilities—Income taxes $ 457 $ 472 Our income tax expense would have been reduced by $456 and $468 in 2020 and 2019 had these uncertain income tax positions been favorably resolved. It is reasonably possible that the amount of unrecognized tax benefits will significantly change due to one or more of the following events in the next 12 months: expiring statutes, audit activity, tax payments, competent authority proceedings related to transfer pricing or final decisions in matters that are the subject of controversy in various taxing jurisdictions in which we operate, including inventory transfer pricing, cost sharing, product royalty and foreign branch arrangements. We are not able to reasonably estimate the amount or the future periods in which changes in unrecognized tax benefits may be resolved. Interest and penalties incurred associated with uncertain tax positions are included in other income (expense), net. In the normal course of business, income tax authorities in various income tax jurisdictions both within the United States and internationally conduct routine audits of our income tax returns

Retirement Plans

Retirement Plans	12 Months Ended
	Dec. 31, 2020
Retirement Benefits [Abstract]
Retirement Plans	RETIREMENT PLANS Defined Contribution Plans We provide certain employees with defined contribution plans and other types of retirement plans. A portion of our retirement plan expense under the defined contribution plans is funded with Stryker common stock. The use of Stryker common stock represents a non-cash operating activity that is not reflected in our Consolidated Statements of Cash Flows. 2020 2019 2018 Plan expense $ 235 $ 205 $ 180 Expense funded with Stryker common stock 34 31 29 Stryker common stock held by plan: Dollar amount 542 470 358 Shares (in millions) 2.2 2.2 2.3 Value as a percentage of total plan assets 11 % 12 % 12 % Defined Benefit Plans Certain of our subsidiaries have both funded and unfunded defined benefit pension plans covering some or all of their employees. Substantially all of the defined benefit pension plans have projected benefit obligations in excess of plan assets. Discount Rate The discount rates were selected using a hypothetical portfolio of high quality bonds on December 31 that would provide the necessary cash flows to match our projected benefit payments. Expected Return on Plan Assets The expected return on plan assets is determined by applying the target allocation in each asset category of plan investments to the anticipated return for each asset category based on historical and projected returns. Components of Net Periodic Pension Cost Net periodic benefit cost: 2020 2019 2018 Service cost $ (63) $ (41) $ (44) Interest cost (8) (12) (11) Expected return on plan assets 13 12 12 Amortization of prior service credit 1 1 1 Recognized actuarial loss (13) (9) (11) Net periodic benefit cost $ (70) $ (49) $ (53) Changes in assets and benefit obligations recognized in OCI: 2020 2019 2018 Net actuarial gain (loss) $ (117) $ (74) $ 11 Recognized net actuarial loss 13 9 10 Prior service (credit) cost and transition amount (1) (1) (1) Total recognized in other comprehensive income (loss) $ (105) $ (66) $ 20 Total recognized in net periodic benefit cost and OCI $ (175) $ (115) $ (33) Weighted-average rates used to determine net periodic benefit cost: Discount rate 1.0 % 1.9 % 1.8 % Expected return on plan assets 2.9 % 3.5 % 3.3 % Rate of compensation increase 2.9 % 2.9 % 2.8 % Weighted-average discount rate used to determine projected benefit obligations 0.8 % 1.0 % 1.9 % The actuarial gain (loss) for all pension plans in 2020 and 2019 was primarily related to a change in the discount rate used to measure the benefit obligations of those plans. Investment Strategy The investment strategy for our defined benefit pension plans is to meet the liabilities of the plans as they fall due and to maximize the return on invested assets within appropriate risk tolerances. 2020 2019 Fair value of plan assets $ 522 $ 428 Benefit obligations (1,118) (869) Funded status $ (596) $ (441) Reported as: Current liabilities—accrued compensation $ (2) $ (2) Noncurrent liabilities—other liabilities (594) (439) Pre-tax amounts recognized in AOCI: Unrecognized net actuarial loss (354) (250) Unrecognized prior service credit 8 9 Total $ (346) $ (241) Change in Benefit Obligations 2020 2019 Beginning projected benefit obligations $ 869 $ 735 Service cost 63 41 Interest cost 8 12 Foreign exchange impact 80 (12) Employee contributions 8 6 Actuarial (gains) losses 110 116 Acquisition — — Benefits paid (20) (29) Ending projected benefit obligations $ 1,118 $ 869 Ending accumulated benefit obligations $ 1,056 $ 830 Change in Plan Assets 2020 2019 Beginning fair value of plan assets $ 428 $ 376 Actual return 30 52 Employer contributions 33 25 Employee contributions 8 6 Foreign exchange impact 37 (5) Acquisition — — Benefits paid (14) (26) Ending fair value of plan assets $ 522 $ 428 Allocation of Plan Assets 2021 Target 2020 Actual 2019 Actual Equity securities 20 % 23 % 22 % Debt securities 45 44 44 Other 35 33 34 Total 100 % 100 % 100 % Valuation of Plan Assets 2020 Level 1 Level 2 Level 3 Total Cash and cash equivalents $ 14 $ — $ — $ 14 Equity securities 23 108 — 131 Corporate debt securities 2 201 — 203 Other 7 63 104 174 Total $ 46 $ 372 $ 104 $ 522 2019 Cash and cash equivalents $ 7 $ — $ — $ 7 Equity securities 23 86 — 109 Corporate debt securities 3 173 — 176 Other 4 52 80 136 Total $ 37 $ 311 $ 80 $ 428 Our Level 3 pension plan assets consist primarily of guaranteed investment contracts with insurance companies. The insurance contracts guarantee us principal repayment and a fixed rate of return. The $24 increase in Level 3 pension plan assets is primarily related to actual returns and acquired assets. We expect to contribute $30 to our defined benefit pension plans in 2021. Estimated Future Benefit Payments 2021 2022 2023 2024 2025 2026-2030 $ 22 $ 21 $ 21 $ 22 $ 24 $ 134

Summary of Quarterly Data (Unau

Summary of Quarterly Data (Unaudited)	12 Months Ended
	Dec. 31, 2020
Quarterly Financial Data [Abstract]
Summary of Quarterly Data (Unaudited)	SUMMARY OF QUARTERLY DATA (UNAUDITED) 2020 Quarters Mar 31 Jun 30 Sep 30 Dec 31 Net sales $ 3,588 $ 2,764 $ 3,737 $ 4,262 Gross profit 2,331 1,548 2,461 2,717 Earnings (loss) before income taxes 590 (87) 780 671 Net earnings (loss) 493 (83) 621 568 Net earnings (loss) per share of common stock: Basic $ 1.32 $ (0.22) $ 1.66 $ 1.51 Diluted $ 1.30 $ (0.22) $ 1.63 $ 1.49 Dividends declared per share of common stock $ 0.575 $ 0.575 $ 0.575 $ 0.63 2019 Quarters Mar 31 Jun 30 Sep 30 Dec 31 Net sales $ 3,516 $ 3,650 $ 3,587 $ 4,131 Gross profit 2,283 2,380 2,330 2,703 Earnings before income taxes 480 565 581 936 Net earnings 412 480 466 725 Net earnings per share of common stock: Basic $ 1.10 $ 1.29 $ 1.24 $ 1.94 Diluted $ 1.09 $ 1.26 $ 1.23 $ 1.90 Dividends declared per share of common stock $ 0.52 $ 0.52 $ 0.52 $ 0.575

Asset Impairments

Asset Impairments	12 Months Ended
	Dec. 31, 2020
Property, Plant and Equipment [Abstract]
Asset Impairments	ASSET IMPAIRMENTSDue to the significant negative impact the COVID-19 pandemic has had on our operations and financial results, we suspended certain in-process investments resulting in charges of $195 to impair certain long-lived assets (primarily the portion of our investment in a new global ERP system that was in-process of being developed for future deployment) and product line and other exit costs in 2020. These charges were included in cost of sales and selling, general and administrative expenses.

Significant Accounting Polici_2

Significant Accounting Policies (Policies)	12 Months Ended
	Dec. 31, 2020
Significant Accounting Policies [Abstract]
Nature of Operations	Stryker (the "Company," "we," "us," or "our") is one of the world's leading medical technology companies and, together with its customers, is driven to make healthcare better. The Company offers innovative products and services in Orthopaedics, Medical and Surgical, and Neurotechnology and Spine that improve patient and hospital outcomes. Our products include implants used in joint replacement and trauma surgeries; surgical equipment and surgical navigation systems; endoscopic and communications systems; patient handling, emergency medical equipment and intensive care disposable products; neurosurgical, neurovascular and spinal devices; as well as other products used in a variety of medical specialties.
Basis of Presentation and Consideration	The Consolidated Financial Statements include the Company and its subsidiaries. All significant intercompany accounts and transactions are eliminated in consolidation. We have no material interests in variable interest entities and none that require consolidation. Certain prior year amounts have been reclassified to conform with current year presentation in our Consolidated Financial Statements, including immaterial reclassifications of segment results and $302 of loaner instrumentation not intended to be sold reclassified from inventories to other noncurrent assets.
Use of Estimates	The preparation of financial statements in conformity with accounting principles generally accepted in the United States (GAAP) requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities on the date of the financial statements and the reported amounts of net sales and expenses in the reporting period. Actual results could differ from those estimates.
Revenue Recognition	Sales are recognized as the performance obligations to deliver products or services are satisfied and are recorded based on the amount of consideration we expect to receive in exchange for satisfying the performance obligations. Our sales are recognized primarily when we transfer control to the customer, which can be on the date of shipment, the date of receipt by the customer or, for most Orthopaedics products, when we have received a purchase order and appropriate notification the product has been used or implanted. Products and services are primarily transferred to customers at a point in time, with some transfers of services taking place over time. Sales represent the amount of consideration we expect to receive from customers in exchange for transferring products and services. Net sales exclude sales, value added and other taxes we collect from customers. Other costs to obtain and fulfill contracts are generally expensed as incurred due to the short-term nature of most of our sales. We extend terms of payment to our customers based on commercially reasonable terms for the markets of our customers, while also considering their credit quality. A provision for estimated sales returns, discounts and rebates is recognized as a reduction of sales in the same period that the sales are recognized. Our estimate of the provision for sales returns has been established based on contract terms with our customers and historical business practices and current trends. Shipping and handling costs charged to customers are included in net sales.
Cost of Sales	Cost of sales is primarily comprised of direct materials and supplies consumed in the manufacture of product, as well as manufacturing labor, depreciation expense and direct overhead expense necessary to acquire and convert the purchased materials and supplies into finished product. Cost of sales also includes the cost to distribute products to customers, inbound freight costs, warehousing costs and other shipping and handling activity.
Research, Development and Engineering Expenses	Research and development costs are charged to expense as incurred. Costs include research, development and engineering activities relating to the development of new products, improvement of existing products, technical support of products and compliance with governmental regulations for the protection of customers and patients. Costs primarily consist of salaries, wages, consulting and depreciation and maintenance of research facilities and equipment.
Selling, General and Administrative Expenses	Selling, general and administrative expense is primarily comprised of selling expenses, marketing expenses, administrative and other indirect overhead costs, amortization of loaner instrumentation, depreciation and amortization expense of non-manufacturing assets and other miscellaneous operating items.
Currency Translation	Financial statements of subsidiaries outside the United States generally are measured using the local currency as the functional currency. Adjustments to translate those statements into United States Dollars are recorded in other comprehensive income (OCI). Transactional exchange gains and losses are included in other income (expense), net.
Cash Equivalents	Highly liquid investments with remaining stated maturities of three months or less when purchased or other money market instruments that are redeemable upon demand are considered cash equivalents and recorded at cost.
Marketable Securities	Marketable securities consist of marketable debt securities, certificates of deposit and mutual funds. Mutual funds are acquired to offset changes in certain liabilities related to deferred compensation arrangements and are expected to be used to settle these liabilities and are recorded in other noncurrent assets. Pursuant to our investment policy, all individual marketable security investments must have a minimum credit quality of single A (Standard & Poor’s and Fitch) and A2 (Moody’s Corporation) at the time of acquisition, while the overall portfolio of marketable securities must maintain a minimum average credit quality of double A (Standard & Poor’s and Fitch) or Aa (Moody’s Corporation). In the event of a rating downgrade below the minimum credit quality subsequent to purchase, the marketable security investment is evaluated to determine the appropriate action to take to minimize the overall risk to our marketable security investment portfolio. Our marketable securities are classified as available-for-sale and trading securities. Investments in trading securities represent participant-directed investments of deferred employee compensation.
Accounts Receivable	Accounts receivable consists of trade and other miscellaneous receivables. An allowance is maintained for doubtful accounts for estimated losses in the collection of accounts receivable. Estimates are made regarding the ability of customers to make required payments based on historical credit experience, current market conditions and expected credit losses. Accounts receivable are written off when all reasonable collection efforts are exhausted.
Inventories	Inventories are stated at the lower of cost or net realizable value, with cost generally determined using the first-in, first-out (FIFO) cost method. For excess and obsolete inventory resulting from the potential inability to sell specific products at prices in excess of current carrying costs, reserves are maintained to reduce current carrying cost to net realizable value.
Financial Instruments	Our financial instruments consist of cash, cash equivalents, marketable securities, accounts receivable, other investments, accounts payable, debt and foreign currency exchange contracts. The carrying value of our financial instruments, with the exception of our senior unsecured notes, approximates fair value on December 31, 2020 and 2019. Refer to Notes 3 and 10 for further details. All marketable securities are recognized at fair value. Adjustments to the fair value of marketable securities that are classified as available-for-sale are recorded as increases or decreases, net of income taxes, within accumulated other comprehensive income (AOCI) in shareholders’ equity and adjustments to the fair value of marketable securities that are classified as trading are recorded in earnings. The amortized cost of marketable debt securities is adjusted for amortization of premiums and discounts to maturity computed under the effective interest method. Such amortization and interest and realized gains and losses are included in other income (expense), net. The cost of securities sold is determined by the specific identification method. We review declines in the fair value of our investments classified as available-for-sale to determine whether the decline in fair value is a result of credit loss or other factors. Impairments of available-for-sale marketable debt securities related to credit loss are included in earnings and impairments related to other factors are recognized within AOCI.
Derivatives	All derivatives are recognized at fair value and reported on a gross basis. We enter into forward currency exchange contracts to mitigate the impact of currency fluctuations on transactions denominated in nonfunctional currencies, thereby limiting our risk that would otherwise result from changes in exchange rates. The periods of the forward currency exchange contracts correspond to the periods of the exposed transactions, with realized gains and losses included in the measurement and recording of transactions denominated in the nonfunctional currencies. All forward currency exchange contracts are recorded at their fair value each period. Forward currency exchange contracts designated as cash flow hedges are designed to hedge the variability of cash flows associated with forecasted transactions denominated in a foreign currency that will take place in the future. These nonfunctional currency exposures principally relate to forecasted intercompany sales and purchases of manufactured products and generally have maturities up to eighteen months. Changes in value of derivatives designated as cash flow hedges are recorded in AOCI on the Consolidated Balance Sheets until earnings are affected by the variability of the underlying cash flows. At that time, the applicable amount of gain or loss from the derivative instrument that is deferred in shareholders’ equity is reclassified into earnings and is included in cost of goods sold in the Consolidated Statements of Earnings. Cash flows associated with these hedges are included in cash from operations in the same category as the cash flows from the items being hedged. Forward currency exchange contracts are used to offset our exposure to the change in value of specific foreign currency denominated assets and liabilities, primarily intercompany payables and receivables. These derivatives are not designated as hedges and, therefore, changes in the value of these forward contracts are recognized in earnings, thereby offsetting the current earnings effect of the related changes in value of foreign currency denominated assets and liabilities. The estimated fair value of our forward currency exchange contracts represents the measurement of the contracts at month-end spot rates as adjusted by current forward points. From time to time, we designate derivative and non-derivative financial instruments as net investment hedges of our investments in certain international subsidiaries. For derivative instruments that are designated and qualify as a net investment hedge, the effective portion of the derivative's gain or loss is recognized in OCI and reported as a component of AOCI. We have elected to use the spot method to assess effectiveness for our derivatives designated as net investment hedges. Accordingly, the change in fair value attributable to changes in the spot rate is recorded in AOCI. We exclude the spot-forward difference from the assessment of hedge effectiveness and amortize this amount separately on a straight-line basis over the term of the forward contracts. This amortization is recognized in Other income (expense). From time to time, we designate forward starting interest rate derivative instruments as cash flow hedges to manage the exposure to interest rate volatility with regard to future issuance and refinancing of debt. Changes in value of derivatives designated as cash flow hedges are recorded in AOCI on the Consolidated Balance Sheets until earnings are affected by the variability of the underlying cash flows. At that time, the applicable amount of gain or loss from the derivative instrument that is deferred in shareholders’ equity is reclassified into earnings and is included in interest expense in the Consolidated Statements of Earnings.
Property, Plant and Equipment	Property, plant and equipment is stated at cost. Depreciation is generally computed by the straight-line method over the estimated useful lives of three three
Goodwill and Other Intangible Assets	Goodwill represents the excess of purchase price over fair value of tangible net assets of acquired businesses at the acquisition date, after amounts allocated to other identifiable intangible assets. Factors that contribute to the recognition of goodwill include synergies that are specific to our business and not available to other market participants and are expected to increase net sales and profits; acquisition of a talented workforce; cost savings opportunities; the strategic benefit of expanding our presence in core and adjacent markets; and diversifying our product portfolio. The fair values of other identifiable intangible assets acquired in a business combination are primarily determined using the income approach. Other intangible assets include, but are not limited to, developed technology, customer and distributor relationships (which reflect expected continued customer or distributor patronage) and trademarks and patents. Intangible assets with determinable useful lives are amortized on a straight-line basis over their estimated useful lives of four In some of our acquisitions, we acquire in-process research and development (IPRD) intangible assets. For acquisitions
Goodwill, Intangibles and Long-Lived Asset Impairment Tests	We perform our annual impairment test for goodwill in the fourth quarter of each year. We consider qualitative indicators of the fair value of a reporting unit when it is unlikely that a reporting unit has impaired goodwill. In certain circumstances, we may also utilize a discounted cash flow analysis that requires certain assumptions and estimates be made regarding market conditions and our future profitability. Indefinite-lived intangible assets are also tested at least annually for impairment by comparing the individual carrying values to the fair value.We review long-lived assets for indicators of impairment whenever events or changes in circumstances indicate that the carrying amount may not be recoverable. The evaluation is performed at the lowest level of identifiable cash flows. Undiscounted cash flows expected to be generated by the related assets are estimated over the asset's useful life based on updated projections. If the evaluation indicates that the carrying amount of the asset may not be recoverable, any potential impairment is measured based upon the fair value of the related asset or asset group as determined by an appropriate market appraisal or other valuation technique. Assets classified as held for sale are recorded at the lower of carrying amount or fair value less costs to sell.
Share-Based Compensation	hare-based compensation is in the form of stock options, restricted stock units (RSUs) and performance stock units (PSUs). Stock options are granted under long-term incentive plans to certain key employees and non-employee directors at an exercise price not less than the fair market value of the underlying common stock, which is the quoted closing price of our common stock on the day prior to the date of grant. The options are granted for periods of up to 10 years and become exercisable in varying installments. We grant RSUs to key employees and non-employee directors and PSUs to certain key employees under our long-term incentive plans. The fair value of RSUs is determined based on the number of shares granted and the quoted closing price of our common stock on the date of grant, adjusted for the fact that RSUs do not include anticipated dividends. RSUs generally vest in one-third increments over a three-year period and are settled in stock. PSUs are earned over a three-year performance cycle and vest in March of the year following the end of that performance cycle. The number of PSUs that will ultimately be earned is based on our performance relative to pre-established goals in that three-year performance cycle. The fair value of PSUs is determined based on the quoted closing price of our common stock on the day of grant. Compensation expense is recognized in the Consolidated Statements of Earnings based on the estimated fair value of the awards on the grant date. Compensation expense recognized reflects an estimate of the number of awards expected to vest after taking into consideration an estimate of award forfeitures based on actual experience and is recognized on a straight-line basis over the requisite service period, which is generally the period required to obtain full vesting. Management expectations related to the achievement of performance goals associated with PSU grants is assessed regularly and that assessment is used to determine whether PSU grants are expected to vest. If
Income Taxes	Deferred income tax assets and liabilities are determined based on differences between financial reporting and income tax bases of assets and liabilities and are measured using the enacted income tax rates in effect for the years in which the differences are expected to reverse. Deferred income tax benefits generally represent the change in net deferred income tax assets and liabilities in the year. Other amounts result from adjustments related to acquisitions and foreign currency as appropriate.We operate in multiple income tax jurisdictions both within the United States and internationally. Accordingly, management must determine the appropriate allocation of income to each of these jurisdictions based on current interpretations of complex income tax regulations. Income tax authorities in these jurisdictions regularly perform audits of our income tax filings. Income tax audits associated with the allocation of this income and other complex issues, including inventory transfer pricing and cost sharing, product royalty and foreign branch arrangements, may require an extended period of time to resolve and may result in significant income tax adjustments if changes to the income allocation are required between jurisdictions with different income tax rates.
New Accounting Pronouncements Not Yet Adopted and Accounting Pronouncements Recently Adopted	New Accounting Pronouncements Not Yet Adopted We evaluate all Accounting Standards Updates (ASUs) issued by the Financial Accounting Standards Board (FASB) for consideration of their applicability. ASUs not included in our disclosures were assessed and determined to be either not applicable or are not expected to have a material impact on our Consolidated Financial Statements. Accounting Pronouncements Recently Adopted On January 1, 2020 we adopted ASU 2016-13, Financial Instruments - Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments . The standard replaces the incurred loss impairment methodology with a methodology that reflects expected credit losses for accounts receivables and loans. The adoption of this update did not have a material impact on our Consolidated Financial Statements. No other new accounting pronouncements were issued or became effective in the period that had, or are expected to have, a material impact on our Consolidated Financial Statements.

Revenue Recognition (Tables)

Revenue Recognition (Tables)	12 Months Ended
	Dec. 31, 2020
Revenue Recognition [Abstract]
Schedule of Disaggregated Revenue	Segment Net Sales Orthopaedics: 2020 2019 2018 Knees $ 1,567 $ 1,815 $ 1,701 Hips 1,206 1,383 1,336 Trauma and Extremities 1,722 1,639 1,580 Other 464 415 374 $ 4,959 $ 5,252 $ 4,991 MedSurg: Instruments $ 1,863 $ 1,959 $ 1,822 Endoscopy 1,763 1,983 1,846 Medical 2,524 2,264 2,118 Sustainability 250 286 259 $ 6,400 $ 6,492 $ 6,045 Neurotechnology and Spine: Neurotechnology $ 1,945 $ 1,983 $ 1,737 Spine 1,047 1,157 828 $ 2,992 $ 3,140 $ 2,565 Total $ 14,351 $ 14,884 $ 13,601 United States Net Sales Orthopaedics: 2020 2019 2018 Knees $ 1,170 $ 1,347 $ 1,244 Hips 777 882 838 Trauma and Extremities 1,139 1,051 1,001 Other 387 334 300 $ 3,473 $ 3,614 $ 3,383 MedSurg: Instruments $ 1,471 $ 1,542 $ 1,424 Endoscopy 1,408 1,577 1,432 Medical 1,910 1,787 1,630 Sustainability 247 283 257 $ 5,036 $ 5,189 $ 4,743 Neurotechnology and Spine: Neurotechnology $ 1,182 $ 1,281 $ 1,115 Spine 764 873 607 $ 1,946 $ 2,154 $ 1,722 Total $ 10,455 $ 10,957 $ 9,848 International Net Sales Orthopaedics: 2020 2019 2018 Knees $ 397 $ 469 $ 457 Hips 429 500 498 Trauma and Extremities 583 588 579 Other 77 81 74 $ 1,486 $ 1,638 $ 1,608 MedSurg: Instruments $ 392 $ 417 $ 398 Endoscopy 355 406 414 Medical 614 477 488 Sustainability 3 3 2 $ 1,364 $ 1,303 $ 1,302 Neurotechnology and Spine: Neurotechnology $ 763 $ 702 $ 622 Spine 283 284 221 $ 1,046 $ 986 $ 843 Total $ 3,896 $ 3,927 $ 3,753

Fair Value Measurements (Tables

Fair Value Measurements (Tables)	12 Months Ended
	Dec. 31, 2020
Fair Value Disclosures [Abstract]
Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis	Assets Measured at Fair Value 2020 2019 Cash and cash equivalents $ 2,943 $ 4,337 Trading marketable securities 171 149 Level 1 - Assets $ 3,114 $ 4,486 Available-for-sale marketable securities: Corporate and asset-backed debt securities $ 38 $ 32 United States agency debt securities 5 2 United States treasury debt securities 36 49 Certificates of deposit 2 5 Total available-for-sale marketable securities $ 81 $ 88 Foreign currency exchange forward contracts 20 226 Interest rate swap asset — 17 Level 2 - Assets $ 101 $ 331 Total assets measured at fair value $ 3,215 $ 4,817 Liabilities Measured at Fair Value 2020 2019 Deferred compensation arrangements $ 171 $ 149 Level 1 - Liabilities $ 171 $ 149 Foreign currency exchange forward contracts $ 160 $ 23 Interest rate swap liability 53 — Level 2 - Liabilities $ 213 $ 23 Contingent consideration: Beginning $ 306 $ 117 Additions 108 298 Change in estimate 9 (10) Settlements (30) (99) Ending $ 393 $ 306 Level 3 - Liabilities $ 393 $ 306 Total liabilities measured at fair value $ 777 $ 478
Available-for-sale Securities	Fair Value of Available for Sale Securities by Maturity 2020 2019 Due in one year or less $ 42 $ 50 Due after one year through three years $ 39 $ 38

Derivative Instruments (Tables)

Derivative Instruments (Tables)	12 Months Ended
	Dec. 31, 2020
Derivative Instruments and Hedging Activities Disclosure [Abstract]
Schedule of Derivative Instruments in Statement of Financial Position, Fair Value	2020 Cash Flow Net Investment Non-Designated Total Gross notional amount $ 949 $ 1,828 $ 5,382 $ 8,159 Maximum term in days 1793 Fair value: Other current assets $ 9 $ — $ 7 $ 16 Other noncurrent assets — 4 — 4 Other current liabilities (12) — (121) (133) Other noncurrent liabilities (1) (26) — (27) Total fair value $ (4) $ (22) $ (114) $ (140) 2019 Gross notional amount $ 801 $ 1,113 $ 6,174 $ 8,088 Maximum term in days 1646 Fair value: Other current assets $ 5 $ — $ 180 $ 185 Other noncurrent assets 1 40 — 41 Other current liabilities (10) — (11) (21) Other noncurrent liabilities (2) — — (2) Total fair value $ (6) $ 40 $ 169 $ 203
Schedule of Derivatives Instruments Statements of Financial Performance and Financial Position, Location	Net Currency Exchange Rate Gains (Losses) Derivative Instrument Recorded in: 2020 2019 2018 Cash Flow Cost of sales $ 5 $ 2 $ 7 Net Investment Other income (expense), net 28 14 — Non-Designated Other income (expense), net (13) (7) (6) Total $ 20 $ 9 $ 1

Accumulated Other Comprehensi_2

Accumulated Other Comprehensive (Loss) Income (AOCI) (Tables)	12 Months Ended
	Dec. 31, 2020
Reclassification Adjustments Out of Accumulated Other Comprehensive Income (AOCI) [Abstract]
Schedule of Accumulated Other Comprehensive Income (Loss)	Marketable Securities Pension Plans Hedges Financial Statement Translation Total 2018 $ (4) $ (137) $ 50 $ (540) $ (631) OCI — (74) 3 101 30 Income taxes — 26 — (21) 5 Reclassifications to: Cost of Sales — — (2) — (2) Other (income) expense 1 8 (5) (14) (10) Income taxes — (2) 1 3 2 Net OCI 1 (42) (3) 69 25 2019 $ (3) $ (179) $ 47 $ (471) $ (606) OCI — (117) (64) (459) (640) Income taxes — 28 17 66 111 Reclassifications to: Cost of Sales — — (5) — (5) Other (income) expense — 12 (6) (28) (22) Income taxes — (3) 1 7 5 Net OCI — (80) (57) (414) (551) 2020 $ (3) $ (259) $ (10) $ (885) $ (1,157)

Acquisitions (Tables)

Acquisitions (Tables)	12 Months Ended
	Dec. 31, 2020
Business Combinations [Abstract]
Allocation Of The Preliminary Purchase Price To The Acquired Net Assets Of Acquisitions	Purchase price allocations for our significant acquisitions are: Purchase Price Allocation of Acquired Net Assets 2020 Wright Tangible assets acquired: Accounts receivable $ 127 Deferred income tax assets 371 Inventory 485 Other assets 344 Debt (1,447) Deferred income tax liabilities (511) Product liabilities (192) Other liabilities (288) Intangible assets: Customer and distributor relationships 181 Developed technology and patents 1,523 Trade name 60 Goodwill 3,428 Purchase price, net of cash acquired $ 4,081 Weighted average life of intangible assets 12 2019 Mobius OrthoSpace Tangible assets acquired: Accounts receivable $ 3 $ 1 Inventory 6 1 Other assets 2 1 Contingent consideration (4) — Other liabilities (10) (29) Intangible assets: Customer relationship 7 — Developed technology and patents 59 120 In-process research and development 98 — Non-compete agreements 9 — Goodwill 303 114 Purchase price, net of cash acquired $ 473 $ 208 Weighted average life of intangible assets 12 18

Contingencies and Commitments (

Contingencies and Commitments (Tables)	12 Months Ended
	Dec. 31, 2020
Commitments and Contingencies Disclosure [Abstract]
Lease, Cost	2020 2019 Right-of-use assets $ 423 $ 384 Lease liabilities, current $ 109 $ 86 Lease liabilities, non-current $ 325 $ 301 Other information: Weighted-average remaining lease term 5.6 years 6.2 years Weighted-average discount rate 2.57 % 3.34 %
Future Purchase Obligations and Minimum Lease Payments	2021 2022 2023 2024 2025 Thereafter Debt repayments $ 761 $ 2 $ 1,670 $ 1,636 $ 1,400 $ 8,646 Purchase obligations $ 1,294 $ 76 $ 58 $ 52 $ 52 $ 55 Minimum lease payments $ 110 $ 87 $ 65 $ 38 $ 30 $ 90

Goodwill and Other Intangible_2

Goodwill and Other Intangible Assets (Tables)	12 Months Ended
	Dec. 31, 2020
Goodwill and Intangible Assets Disclosure [Abstract]
Summary of the Company's Other Intangible Assets	Summary of Other Intangible Assets Weighted Average Amortization Period (Years) Gross Less Net Developed technologies 2020 13 $ 5,305 $ 1,573 $ 3,732 2019 14 3,731 1,271 2,460 Customer relationships 2020 15 $ 2,352 $ 988 $ 1,364 2019 16 2,160 848 1,312 Patents 2020 12 $ 346 $ 278 $ 68 2019 11 348 265 83 Trademarks 2020 17 $ 428 $ 162 $ 266 2019 18 362 136 226 In-process research and development 2020 N/A $ 97 $ — $ 97 2019 N/A 110 — 110 Other 2020 8 $ 128 $ 101 $ 27 2019 8 125 89 36 Total 2020 14 $ 8,656 $ 3,102 $ 5,554 2019 14 6,836 2,609 4,227
Changes in the Net Carrying Amount of Goodwill by Segment	Changes in the Net Carrying Value of Goodwill by Segment Orthopaedics MedSurg Neurotechnology and Spine Total 2018 $ 2,399 $ 3,581 $ 2,583 $ 8,563 Additions and adjustments — 229 318 547 Foreign exchange (13) (11) (17) (41) 2019 $ 2,386 $ 3,799 $ 2,884 $ 9,069 Additions and adjustments 3,551 1 7 3,559 Foreign exchange 67 31 52 150 2020 $ 6,004 $ 3,831 $ 2,943 $ 12,778
Estimated Amortization Expense	Estimated Amortization Expense 2021 2022 2023 2024 2025 $ 600 $ 588 $ 567 $ 540 $ 518

Capital Stock (Tables)

Capital Stock (Tables)	12 Months Ended
	Dec. 31, 2020
Capital Stock [Abstract]
Schedule of Fair Value Assumptions	Option Value and Assumptions 2020 2019 2018 Weighted-average fair value per share $ 39.34 $ 36.30 $ 28.52 Assumptions: Risk-free interest rate 1.4 % 2.6 % 2.7 % Expected dividend yield 1.0 % 1.1 % 1.2 % Expected stock price volatility 18.9 % 18.3 % 16.8 % Expected option life (years) 5.8 5.9 6.0
Summary of Stock Option Activity	2020 Stock Option Activity Shares Weighted Weighted-Average Aggregate Outstanding January 1 12.8 $ 113.10 Granted 1.8 216.28 Exercised (2.0) 83.75 Canceled (0.4) 162.98 Outstanding December 31 12.2 $ 131.72 5.9 $ 1,388.1 Exercisable December 31 6.8 $ 99.09 4.4 $ 995.7 Options expected to vest 4.9 $ 171.06 7.7 $ 364.3
Summary of RSU and PSU Activity	Restricted Stock Units (RSUs) and Performance Stock Units (PSUs) Activity Shares Weighted Average RSUs PSUs RSUs PSUs Nonvested on January 1 0.8 0.2 $ 158.80 $ 152.44 Granted 0.4 0.1 208.96 217.73 Vested (0.4) (0.1) 149.09 122.41 Canceled or forfeited — — 154.38 166.99 Nonvested on December 31 0.8 0.2 $ 187.72 $ 185.46

Debt and Credit Facilities (Tab

Debt and Credit Facilities (Tables)	12 Months Ended
	Dec. 31, 2020
Long-term Debt, Unclassified [Abstract]
Maturities Of Long-Term Debt Disclosures	Summary of Total Debt Senior unsecured notes: Rate Due 2020 2019 4.375% January 15, 2020 $ — $ 500 Variable November 30, 2020 — 333 2.625% March 15, 2021 750 749 1.125% November 30, 2023 668 609 0.600% December 1, 2023 597 — 3.375% May 15, 2024 590 587 0.250% December 3, 2024 1,030 938 1.150% June 15, 2025 644 — 3.375% November 1, 2025 747 746 3.500% March 15, 2026 992 991 2.125% November 30, 2027 909 829 3.650% March 7, 2028 596 596 0.750% March 1, 2029 969 884 1.950% June 15, 2030 989 — 2.625% November 30, 2030 782 712 1.000% December 3, 2031 903 823 4.100% April 1, 2043 392 391 4.375% May 15, 2044 395 395 4.625% March 15, 2046 981 981 2.900% June 15, 2050 641 — Term loan 400 — Other 16 26 Total debt $ 13,991 $ 11,090 Less current maturities 761 859 Total long-term debt $ 13,230 $ 10,231 Unamortized debt issuance costs $ 71 $ 58 Borrowing capacity on existing facilities $ 2,903 $ 1,546 Fair value of senior unsecured notes $ 15,022 $ 11,910

Income Taxes (Tables)

Income Taxes (Tables)	12 Months Ended
	Dec. 31, 2020
Income Tax Disclosure [Abstract]
Schedule of Reconciliation of U.S. Statutory Income Tax Rate to Company's Effective Income Tax Rate from Continuing Operations	Effective Income Tax Rate Reconciliation 2020 2019 2018 United States federal statutory rate 21.0 % 21.0 % 21.0 % United States state and local income taxes, less federal deduction 0.1 1.7 0.4 Foreign income tax at rates other than 21% (3.3) (4.6) (6.5) Tax Cuts and Jobs Act of 2017 transition tax — — 2.2 Tax Cuts and Jobs Act of 2017 deferred tax changes — — (0.6) Tax related to repatriation of foreign earnings 3.0 (0.5) 0.5 Intellectual property transfer (1.4) 3.5 (63.8) Other (1.2) (2.4) (4.0) Effective income tax rate 18.2 % 18.7 % (50.8) %
Schedule of Provision for Income Taxes	Earnings Before Income Taxes 2020 2019 2018 United States $ 239 $ 366 $ 509 International 1,715 2,196 1,847 Total $ 1,954 $ 2,562 $ 2,356 Components of Income Tax Expense (Benefit) Current income tax expense: 2020 2019 2018 United States federal $ 80 $ (17) $ 178 United States state and local 20 46 30 International 207 324 177 Total current income tax expense $ 307 $ 353 $ 385 Deferred income tax (benefit) expense: United States federal $ 1 $ 10 $ (44) United States state and local (25) (1) (20) International 72 117 (1,518) Total deferred income tax (benefit) expense $ 48 $ 126 $ (1,582) Total income tax (benefit) expense $ 355 $ 479 $ (1,197)
Schedule of Difference in Income Tax Effects Comprising Company's Deferred Income Tax Assets and Liabilities	Deferred Income Tax Assets and Liabilities Deferred income tax assets: 2020 2019 Inventories $ 434 $ 415 Product-related liabilities 48 57 Other accrued expenses 512 221 Depreciation and amortization 1,269 1,363 State income taxes 108 65 Share-based compensation 56 49 Net operating loss carryforwards 373 95 Other 263 207 Total deferred income tax assets $ 3,063 $ 2,472 Less valuation allowances (203) (75) Net deferred income tax assets $ 2,860 $ 2,397 Deferred Income Tax Assets and Liabilities Deferred income tax liabilities: 2020 2019 Depreciation and amortization $ (1,286) $ (893) Undistributed earnings (161) (37) Other — — Total deferred income tax liabilities $ (1,447) $ (930) Net deferred income tax assets $ 1,413 $ 1,467 Reported as: Noncurrent deferred income tax assets $ 1,530 $ 1,575 Noncurrent liabilities—Other liabilities (117) (108) Total $ 1,413 $ 1,467
Schedule of Unresolved Income Tax Positions	Uncertain Income Tax Positions 2020 2019 Beginning uncertain tax positions $ 472 $ 528 Increases related to current year income tax positions 12 62 Increases related to prior year income tax positions 5 5 Decreases related to prior year income tax positions: Settlements and resolutions of income tax audits (41) (78) Statute of limitations expirations and other (7) (40) Foreign currency translation 16 (5) Ending uncertain tax positions $ 457 $ 472 Reported as: Noncurrent liabilities—Income taxes $ 457 $ 472

Retirement Plans (Tables)

Retirement Plans (Tables)	12 Months Ended
	Dec. 31, 2020
Retirement Benefits [Abstract]
Defined Contribution Plan Disclosures	2020 2019 2018 Plan expense $ 235 $ 205 $ 180 Expense funded with Stryker common stock 34 31 29 Stryker common stock held by plan: Dollar amount 542 470 358 Shares (in millions) 2.2 2.2 2.3 Value as a percentage of total plan assets 11 % 12 % 12 %
Schedule of Costs of Retirement Plans	Components of Net Periodic Pension Cost Net periodic benefit cost: 2020 2019 2018 Service cost $ (63) $ (41) $ (44) Interest cost (8) (12) (11) Expected return on plan assets 13 12 12 Amortization of prior service credit 1 1 1 Recognized actuarial loss (13) (9) (11) Net periodic benefit cost $ (70) $ (49) $ (53) Changes in assets and benefit obligations recognized in OCI: 2020 2019 2018 Net actuarial gain (loss) $ (117) $ (74) $ 11 Recognized net actuarial loss 13 9 10 Prior service (credit) cost and transition amount (1) (1) (1) Total recognized in other comprehensive income (loss) $ (105) $ (66) $ 20 Total recognized in net periodic benefit cost and OCI $ (175) $ (115) $ (33) Weighted-average rates used to determine net periodic benefit cost: Discount rate 1.0 % 1.9 % 1.8 % Expected return on plan assets 2.9 % 3.5 % 3.3 % Rate of compensation increase 2.9 % 2.9 % 2.8 % Weighted-average discount rate used to determine projected benefit obligations 0.8 % 1.0 % 1.9 %
Schedule of Defined Benefit Plans Disclosures	2020 2019 Fair value of plan assets $ 522 $ 428 Benefit obligations (1,118) (869) Funded status $ (596) $ (441) Reported as: Current liabilities—accrued compensation $ (2) $ (2) Noncurrent liabilities—other liabilities (594) (439) Pre-tax amounts recognized in AOCI: Unrecognized net actuarial loss (354) (250) Unrecognized prior service credit 8 9 Total $ (346) $ (241)
Schedule of Changes in Accumulated Postemployment Benefit Obligations	Change in Benefit Obligations 2020 2019 Beginning projected benefit obligations $ 869 $ 735 Service cost 63 41 Interest cost 8 12 Foreign exchange impact 80 (12) Employee contributions 8 6 Actuarial (gains) losses 110 116 Acquisition — — Benefits paid (20) (29) Ending projected benefit obligations $ 1,118 $ 869 Ending accumulated benefit obligations $ 1,056 $ 830
Schedule of Changes in Fair Value of Plan Assets	Change in Plan Assets 2020 2019 Beginning fair value of plan assets $ 428 $ 376 Actual return 30 52 Employer contributions 33 25 Employee contributions 8 6 Foreign exchange impact 37 (5) Acquisition — — Benefits paid (14) (26) Ending fair value of plan assets $ 522 $ 428 Valuation of Plan Assets 2020 Level 1 Level 2 Level 3 Total Cash and cash equivalents $ 14 $ — $ — $ 14 Equity securities 23 108 — 131 Corporate debt securities 2 201 — 203 Other 7 63 104 174 Total $ 46 $ 372 $ 104 $ 522 2019 Cash and cash equivalents $ 7 $ — $ — $ 7 Equity securities 23 86 — 109 Corporate debt securities 3 173 — 176 Other 4 52 80 136 Total $ 37 $ 311 $ 80 $ 428
Schedule of Allocation of Plan Assets	Allocation of Plan Assets 2021 Target 2020 Actual 2019 Actual Equity securities 20 % 23 % 22 % Debt securities 45 44 44 Other 35 33 34 Total 100 % 100 % 100 %
Schedule of Expected Benefit Payments	Estimated Future Benefit Payments 2021 2022 2023 2024 2025 2026-2030 $ 22 $ 21 $ 21 $ 22 $ 24 $ 134

Summary of Quarterly Data (Un_2

Summary of Quarterly Data (Unaudited) (Tables)	12 Months Ended
	Dec. 31, 2020
Quarterly Financial Data [Abstract]
Summary of Quarterly Data	2020 Quarters Mar 31 Jun 30 Sep 30 Dec 31 Net sales $ 3,588 $ 2,764 $ 3,737 $ 4,262 Gross profit 2,331 1,548 2,461 2,717 Earnings (loss) before income taxes 590 (87) 780 671 Net earnings (loss) 493 (83) 621 568 Net earnings (loss) per share of common stock: Basic $ 1.32 $ (0.22) $ 1.66 $ 1.51 Diluted $ 1.30 $ (0.22) $ 1.63 $ 1.49 Dividends declared per share of common stock $ 0.575 $ 0.575 $ 0.575 $ 0.63 2019 Quarters Mar 31 Jun 30 Sep 30 Dec 31 Net sales $ 3,516 $ 3,650 $ 3,587 $ 4,131 Gross profit 2,283 2,380 2,330 2,703 Earnings before income taxes 480 565 581 936 Net earnings 412 480 466 725 Net earnings per share of common stock: Basic $ 1.10 $ 1.29 $ 1.24 $ 1.94 Diluted $ 1.09 $ 1.26 $ 1.23 $ 1.90 Dividends declared per share of common stock $ 0.52 $ 0.52 $ 0.52 $ 0.575

Segment and Geographic Data (Ta

Segment and Geographic Data (Tables)	12 Months Ended
	Dec. 31, 2020
Segment Reporting [Abstract]
Reconciliation of Operating Profit (Loss) from Segments to Consolidated	Segment Results 2020 2019 2018 Orthopaedics $ 4,959 $ 5,252 $ 4,991 MedSurg $ 6,400 6,492 6,045 Neurotechnology & Spine 2,992 3,140 2,565 Net sales $ 14,351 $ 14,884 $ 13,601 Orthopaedics $ 344 $ 348 $ 350 MedSurg 362 379 285 Neurotechnology & Spine 248 218 176 Segment depreciation and amortization $ 954 $ 945 $ 811 Corporate and Other 122 99 155 Total depreciation and amortization $ 1,076 $ 1,044 $ 966 Orthopaedics $ 1,518 $ 1,907 $ 1,804 MedSurg 1,837 1,642 1,444 Neurotechnology & Spine 647 839 700 Segment operating income $ 4,002 $ 4,388 $ 3,948 Items not allocated to segments: Corporate and Other $ (503) $ (480) $ (431) Acquisition and integration-related charges (242) (275) (123) Amortization of intangible assets (472) (464) (417) Restructuring-related and other charges (458) (226) (220) Medical device regulations (81) (62) (12) Recall-related matters (17) (192) (23) Regulatory and legal matters (6) 24 (185) Consolidated operating income $ 2,223 $ 2,713 $ 2,537
Sales and Other Financial Information by Business Segment	Segment Assets and Capital Spending Assets: 2020 2019 2018 Orthopaedics $ 14,910 $ 9,085 $ 8,873 MedSurg 17,901 12,066 10,417 Neurotechnology & Spine 529 7,646 7,260 Total segment assets $ 33,340 $ 28,797 $ 26,550 Corporate and Other 990 1,370 679 Total assets $ 34,330 $ 30,167 $ 27,229 Capital spending: Orthopaedics $ 140 $ 125 $ 134 MedSurg 174 265 217 Neurotechnology & Spine 28 29 31 Total segment capital spending $ 342 $ 419 $ 382 Corporate and Other 145 230 190 Total capital spending $ 487 $ 649 $ 572
Geographic Information on Net Sales and Long-Lived Assets	Geographic Information Net Sales Net Property, Plant and Equipment 2020 2019 2018 2020 2019 United States $ 10,455 $ 10,957 $ 9,848 $ 1,645 $ 1,561 Europe, Middle East, Africa 1,818 1,888 1,793 938 838 Asia Pacific 1,630 1,617 1,532 91 95 Other countries 448 422 428 78 73 Total $ 14,351 $ 14,884 $ 13,601 $ 2,752 $ 2,567

Significant Accounting Polici_3

Significant Accounting Policies (Narrative) (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019
Inventories	$ 3,494	$ 2,980
Other noncurrent assets	2,009	$ 1,671
Revision of Prior Period, Reclassification, Adjustment
Inventories	302
Other noncurrent assets	$ (302)
Employee Stock Option
Vesting period	10 years
Restricted Stock Units (RSUs)
Performance period	3 years
Performance Stock Units (PSUs)
Vesting period	3 years
Minimum
Finite-lived intangible asset, useful life	4 years
Maximum
Finite-lived intangible asset, useful life	40 years
Building and Improvements | Minimum
Property, plant and equipment useful life	3 years
Building and Improvements | Maximum
Property, plant and equipment useful life	30 years
Machinery and Equipment | Minimum
Property, plant and equipment useful life	3 years
Machinery and Equipment | Maximum
Property, plant and equipment useful life	15 years

Revenue Recognition - Narrative

Revenue Recognition - Narrative (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019
Revenue Recognition [Abstract]
Percentage of sales recognized as services over time (less than)	10.00%
Contract liabilities	$ 416	$ 313

Revenue Recognition - Disaggreg

Revenue Recognition - Disaggregated Sales Analysis (Details) - USD ($) $ in Millions	3 Months Ended								12 Months Ended
	Dec. 31, 2020	Sep. 30, 2020	Jun. 30, 2020	Mar. 31, 2020	Dec. 31, 2019	Sep. 30, 2019	Jun. 30, 2019	Mar. 31, 2019	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018
Disaggregation of Revenue [Line Items]
Net sales	$ 4,262	$ 3,737	$ 2,764	$ 3,588	$ 4,131	$ 3,587	$ 3,650	$ 3,516	$ 14,351	$ 14,884	$ 13,601
United States
Disaggregation of Revenue [Line Items]
Net sales									10,455	10,957	9,848
International
Disaggregation of Revenue [Line Items]
Net sales									3,896	3,927	3,753
Orthopaedics
Disaggregation of Revenue [Line Items]
Net sales									4,959	5,252	4,991
Orthopaedics | United States
Disaggregation of Revenue [Line Items]
Net sales									3,473	3,614	3,383
Orthopaedics | International
Disaggregation of Revenue [Line Items]
Net sales									1,486	1,638	1,608
Orthopaedics | Knees
Disaggregation of Revenue [Line Items]
Net sales									1,567	1,815	1,701
Orthopaedics | Knees | United States
Disaggregation of Revenue [Line Items]
Net sales									1,170	1,347	1,244
Orthopaedics | Knees | International
Disaggregation of Revenue [Line Items]
Net sales									397	469	457
Orthopaedics | Hips
Disaggregation of Revenue [Line Items]
Net sales									1,206	1,383	1,336
Orthopaedics | Hips | United States
Disaggregation of Revenue [Line Items]
Net sales									777	882	838
Orthopaedics | Hips | International
Disaggregation of Revenue [Line Items]
Net sales									429	500	498
Orthopaedics | Trauma and Extremities
Disaggregation of Revenue [Line Items]
Net sales									1,722	1,639	1,580
Orthopaedics | Trauma and Extremities | United States
Disaggregation of Revenue [Line Items]
Net sales									1,139	1,051	1,001
Orthopaedics | Trauma and Extremities | International
Disaggregation of Revenue [Line Items]
Net sales									583	588	579
Orthopaedics | Other
Disaggregation of Revenue [Line Items]
Net sales									464	415	374
Orthopaedics | Other | United States
Disaggregation of Revenue [Line Items]
Net sales									387	334	300
Orthopaedics | Other | International
Disaggregation of Revenue [Line Items]
Net sales									77	81	74
MedSurg
Disaggregation of Revenue [Line Items]
Net sales									6,400	6,492	6,045
MedSurg | United States
Disaggregation of Revenue [Line Items]
Net sales									5,036	5,189	4,743
MedSurg | International
Disaggregation of Revenue [Line Items]
Net sales									1,364	1,303	1,302
MedSurg | Instruments
Disaggregation of Revenue [Line Items]
Net sales									1,863	1,959	1,822
MedSurg | Instruments | United States
Disaggregation of Revenue [Line Items]
Net sales									1,471	1,542	1,424
MedSurg | Instruments | International
Disaggregation of Revenue [Line Items]
Net sales									392	417	398
MedSurg | Endoscopy
Disaggregation of Revenue [Line Items]
Net sales									1,763	1,983	1,846
MedSurg | Endoscopy | United States
Disaggregation of Revenue [Line Items]
Net sales									1,408	1,577	1,432
MedSurg | Endoscopy | International
Disaggregation of Revenue [Line Items]
Net sales									355	406	414
MedSurg | Medical
Disaggregation of Revenue [Line Items]
Net sales									2,524	2,264	2,118
MedSurg | Medical | United States
Disaggregation of Revenue [Line Items]
Net sales									1,910	1,787	1,630
MedSurg | Medical | International
Disaggregation of Revenue [Line Items]
Net sales									614	477	488
MedSurg | Sustainability
Disaggregation of Revenue [Line Items]
Net sales									250	286	259
MedSurg | Sustainability | United States
Disaggregation of Revenue [Line Items]
Net sales									247	283	257
MedSurg | Sustainability | International
Disaggregation of Revenue [Line Items]
Net sales									3	3	2
Neurotechnology and Spine
Disaggregation of Revenue [Line Items]
Net sales									2,992	3,140	2,565
Neurotechnology and Spine | United States
Disaggregation of Revenue [Line Items]
Net sales									1,946	2,154	1,722
Neurotechnology and Spine | International
Disaggregation of Revenue [Line Items]
Net sales									1,046	986	843
Neurotechnology and Spine | Neurotechnology
Disaggregation of Revenue [Line Items]
Net sales									1,945	1,983	1,737
Neurotechnology and Spine | Neurotechnology | United States
Disaggregation of Revenue [Line Items]
Net sales									1,182	1,281	1,115
Neurotechnology and Spine | Neurotechnology | International
Disaggregation of Revenue [Line Items]
Net sales									763	702	622
Neurotechnology and Spine | Spine
Disaggregation of Revenue [Line Items]
Net sales									1,047	1,157	828
Neurotechnology and Spine | Spine | United States
Disaggregation of Revenue [Line Items]
Net sales									764	873	607
Neurotechnology and Spine | Spine | International
Disaggregation of Revenue [Line Items]
Net sales									$ 283	$ 284	$ 221

Fair Value Measurements (Valuat

Fair Value Measurements (Valuation Of Financial Instruments By Pricing Categories) (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019
Assets
Available-for-sale marketable securities:	$ 81	$ 88
Total assets measured at fair value	3,215	4,817
Contingent Consideration Arrangements, Change in Amount of Contingent Consideration [Abstract]
Total liabilities measured at fair value	777	478
(Level 1)
Assets
Available-for-sale marketable securities	2,943	4,337
Trading marketable securities	171	149
Total assets measured at fair value	3,114	4,486
Liabilities:
Deferred compensation arrangements	171	149
Contingent Consideration Arrangements, Change in Amount of Contingent Consideration [Abstract]
Total liabilities measured at fair value	171	149
(Level 2)
Assets
Total assets measured at fair value	101	331
Contingent Consideration Arrangements, Change in Amount of Contingent Consideration [Abstract]
Total liabilities measured at fair value	213	23
(Level 2) | Foreign currency exchange forward contracts
Assets
Foreign currency exchange forward contracts	20	226
Interest rate swap asset	20	226
Liabilities:
Foreign currency exchange forward contracts	160	23
(Level 2) | Interest rate swap
Assets
Foreign currency exchange forward contracts	0	17
Interest rate swap asset	0	17
Liabilities:
Foreign currency exchange forward contracts	53	0
(Level 2) | Available-for-sale marketable securities:
Assets
Available-for-sale marketable securities:	81	88
(Level 2) | Available-for-sale marketable securities: | Corporate and asset-backed debt securities
Assets
Available-for-sale marketable securities:	38	32
(Level 2) | Available-for-sale marketable securities: | United States agency debt securities
Assets
Available-for-sale marketable securities:	5	2
(Level 2) | Available-for-sale marketable securities: | United States treasury debt securities
Assets
Available-for-sale marketable securities:	36	49
(Level 2) | Available-for-sale marketable securities: | Certificates of deposit
Assets
Available-for-sale marketable securities:	2	5
(Level 3)
Contingent Consideration Arrangements, Change in Amount of Contingent Consideration [Abstract]
Beginning	306	117
Additions	108	298
Change in estimate	9	(10)
Settlements	(30)	(99)
Ending	393	306
Total liabilities measured at fair value	$ 393	$ 306

Fair Value Measurements (Availa

Fair Value Measurements (Available-For-Sale Securities) (Details) - USD ($) $ in Millions	Dec. 31, 2020	Dec. 31, 2019
Fair Value Disclosures [Abstract]
Due in one year or less	$ 42	$ 50
Due after one year through three years	$ 39	$ 38

Fair Value Measurements (Narrat

Fair Value Measurements (Narrative) (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018
Marketable securities, gain (loss)	$ 102	$ 155	$ 119

Derivative Instruments (Forward

Derivative Instruments (Forward Currency Exchange Contracts) (Details) - Foreign currency exchange forward contracts $ in Millions	12 Months Ended
	Dec. 31, 2020USD ($)	Dec. 31, 2019USD ($)	Nov. 30, 2020EUR (€)	Dec. 31, 2019EUR (€)	Jul. 31, 2019EUR (€)	Nov. 30, 2018EUR (€)
Derivative [Line Items]
Maximum term	1793 days	1646 days
Derivative, fair value, net	$ (140)	$ 203
Notional amount	8,159	8,088
Other current assets
Derivative [Line Items]
Derivative asset	16	185
Other noncurrent assets
Derivative [Line Items]
Derivative asset	4	41
Other current liabilities
Derivative [Line Items]
Derivative liability	(133)	(21)
Other noncurrent liabilities
Derivative [Line Items]
Derivative liability	(27)	(2)
Designated as Hedging Instrument
Derivative [Line Items]
Derivative, fair value, net	(22)	40
Notional amount	1,828	1,113	€ 500,000,000	€ 2,400,000,000	€ 1,000,000,000	€ 2,250,000,000
Designated as Hedging Instrument | Other current assets
Derivative [Line Items]
Derivative asset	0	0
Designated as Hedging Instrument | Other noncurrent assets
Derivative [Line Items]
Derivative asset	4	40
Designated as Hedging Instrument | Other current liabilities
Derivative [Line Items]
Derivative liability	0	0
Designated as Hedging Instrument | Other noncurrent liabilities
Derivative [Line Items]
Derivative liability	(26)	0
Not Designated as Hedging Instrument
Derivative [Line Items]
Derivative, fair value, net	(114)	169
Notional amount	5,382	6,174
Not Designated as Hedging Instrument | Other current assets
Derivative [Line Items]
Derivative asset	7	180
Not Designated as Hedging Instrument | Other noncurrent assets
Derivative [Line Items]
Derivative asset	0	0
Not Designated as Hedging Instrument | Other current liabilities
Derivative [Line Items]
Derivative liability	(121)	(11)
Not Designated as Hedging Instrument | Other noncurrent liabilities
Derivative [Line Items]
Derivative liability	0	0
Cash Flow Hedging | Designated as Hedging Instrument
Derivative [Line Items]
Derivative, fair value, net	(4)	(6)
Notional amount	949	801
Cash Flow Hedging | Designated as Hedging Instrument | Other current assets
Derivative [Line Items]
Derivative asset	9	5
Cash Flow Hedging | Designated as Hedging Instrument | Other noncurrent assets
Derivative [Line Items]
Derivative asset	0	1
Cash Flow Hedging | Designated as Hedging Instrument | Other current liabilities
Derivative [Line Items]
Derivative liability	(12)	(10)
Cash Flow Hedging | Designated as Hedging Instrument | Other noncurrent liabilities
Derivative [Line Items]
Derivative liability	$ (1)	$ (2)

Derivative Instruments (Narrati

Derivative Instruments (Narrative) (Details) $ in Millions	12 Months Ended
	Dec. 31, 2020USD ($)	Dec. 31, 2019USD ($)	Dec. 31, 2018USD ($)	Nov. 30, 2020EUR (€)	Jun. 30, 2020USD ($)	Dec. 31, 2019EUR (€)	Jul. 31, 2019EUR (€)	Nov. 30, 2018EUR (€)
Derivative Instruments, Gain (Loss) [Line Items]
Repayments of long-term debt	$ 2,297	$ 1,342	$ 669
Debt instrument, repurchased face amount | €				€ 300,000,000
Foreign currency exchange forward contracts
Derivative Instruments, Gain (Loss) [Line Items]
Notional amount	8,159	8,088
Designated as Hedging Instrument | Foreign currency exchange forward contracts
Derivative Instruments, Gain (Loss) [Line Items]
Notional amount	1,828	$ 1,113		€ 500,000,000		€ 2,400,000,000	€ 1,000,000,000	€ 2,250,000,000
Fair value of designated net investment hedges	(386)
Gains on derivatives designated as hedges	(2)
Designated as Hedging Instrument | Interest rate swap
Derivative Instruments, Gain (Loss) [Line Items]
Notional amount	750
Gains on derivatives designated as hedges	6
Derivative notional amount terminated					$ 500	€ 600,000,000
Pretax gains recorded in AOCI	$ (53)

Derivative Instruments (Movemen

Derivative Instruments (Movements out of OCI) (Details) - Foreign currency exchange forward contracts - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018
Derivative [Line Items]
Foreign currency transaction gains (losses)	$ 20	$ 9	$ 1
Cost of sales
Derivative [Line Items]
Foreign currency transaction gains (losses)	5	2	7
Designated as Hedging Instrument
Derivative [Line Items]
Derivatives used in Net Investment Hedge, Gain (Loss), Reclassified to Earnings, Net of Tax	33
Designated as Hedging Instrument | Other income (expense), net
Derivative [Line Items]
Foreign currency transaction gains (losses)	28	14	0
Not Designated as Hedging Instrument | Other income (expense), net
Derivative [Line Items]
Foreign currency transaction gains (losses)	$ (13)	$ (7)	$ (6)

Accumulated Other Comprehensi_3

Accumulated Other Comprehensive (Loss) Income (AOCI) (Schedule of Amounts Recognized in Other Comprehensive Income (Loss)) (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018
Accumulated Other Comprehensive Income (Loss), Net of Tax [Roll Forward]
Accumulated Other Comprehensive Income (Loss), Beginning of Period	$ (606)	$ (631)
OCI	(640)	30
Income taxes	111	5
Cost of sales	5,294	5,188	$ 4,663
Other (income) expense	(269)	(151)	(181)
Income taxes	355	479	(1,197)
Other comprehensive income (loss)	(551)	25	(78)
Accumulated Other Comprehensive Income (Loss), End of Period	(1,157)	(606)	(631)
Reclassification out of Accumulated Other Comprehensive Income
Accumulated Other Comprehensive Income (Loss), Net of Tax [Roll Forward]
Income taxes	5	2
Other comprehensive income (loss)	(551)	25
Reclassification out of Accumulated Other Comprehensive Income | Cost of Sales
Accumulated Other Comprehensive Income (Loss), Net of Tax [Roll Forward]
Cost of sales	(5)	(2)
Reclassification out of Accumulated Other Comprehensive Income | Other (income) expense
Accumulated Other Comprehensive Income (Loss), Net of Tax [Roll Forward]
Other (income) expense	(22)	(10)
Marketable Securities
Accumulated Other Comprehensive Income (Loss), Net of Tax [Roll Forward]
Accumulated Other Comprehensive Income (Loss), Beginning of Period	(3)	(4)
OCI	0	0
Income taxes	0	0
Accumulated Other Comprehensive Income (Loss), End of Period	(3)	(3)	(4)
Marketable Securities | Reclassification out of Accumulated Other Comprehensive Income
Accumulated Other Comprehensive Income (Loss), Net of Tax [Roll Forward]
Income taxes	0	0
Other comprehensive income (loss)	0	1
Marketable Securities | Reclassification out of Accumulated Other Comprehensive Income | Cost of Sales
Accumulated Other Comprehensive Income (Loss), Net of Tax [Roll Forward]
Cost of sales	0	0
Marketable Securities | Reclassification out of Accumulated Other Comprehensive Income | Other (income) expense
Accumulated Other Comprehensive Income (Loss), Net of Tax [Roll Forward]
Other (income) expense	0	1
Pension Plans
Accumulated Other Comprehensive Income (Loss), Net of Tax [Roll Forward]
Accumulated Other Comprehensive Income (Loss), Beginning of Period	(179)	(137)
OCI	(117)	(74)
Income taxes	28	26
Accumulated Other Comprehensive Income (Loss), End of Period	(259)	(179)	(137)
Pension Plans | Reclassification out of Accumulated Other Comprehensive Income
Accumulated Other Comprehensive Income (Loss), Net of Tax [Roll Forward]
Income taxes	(3)	(2)
Other comprehensive income (loss)	(80)	(42)
Pension Plans | Reclassification out of Accumulated Other Comprehensive Income | Cost of Sales
Accumulated Other Comprehensive Income (Loss), Net of Tax [Roll Forward]
Cost of sales	0	0
Pension Plans | Reclassification out of Accumulated Other Comprehensive Income | Other (income) expense
Accumulated Other Comprehensive Income (Loss), Net of Tax [Roll Forward]
Other (income) expense	12	8
Hedges
Accumulated Other Comprehensive Income (Loss), Net of Tax [Roll Forward]
Accumulated Other Comprehensive Income (Loss), Beginning of Period	47	50
OCI	(64)	3
Income taxes	17	0
Accumulated Other Comprehensive Income (Loss), End of Period	(10)	47	50
Hedges | Reclassification out of Accumulated Other Comprehensive Income
Accumulated Other Comprehensive Income (Loss), Net of Tax [Roll Forward]
Income taxes	1	1
Other comprehensive income (loss)	(57)	(3)
Hedges | Reclassification out of Accumulated Other Comprehensive Income | Cost of Sales
Accumulated Other Comprehensive Income (Loss), Net of Tax [Roll Forward]
Cost of sales	(5)	(2)
Hedges | Reclassification out of Accumulated Other Comprehensive Income | Other (income) expense
Accumulated Other Comprehensive Income (Loss), Net of Tax [Roll Forward]
Other (income) expense	(6)	(5)
Financial Statement Translation
Accumulated Other Comprehensive Income (Loss), Net of Tax [Roll Forward]
Accumulated Other Comprehensive Income (Loss), Beginning of Period	(471)	(540)
OCI	(459)	101
Income taxes	66	(21)
Accumulated Other Comprehensive Income (Loss), End of Period	(885)	(471)	$ (540)
Financial Statement Translation | Reclassification out of Accumulated Other Comprehensive Income
Accumulated Other Comprehensive Income (Loss), Net of Tax [Roll Forward]
Income taxes	7	3
Other comprehensive income (loss)	(414)	69
Financial Statement Translation | Reclassification out of Accumulated Other Comprehensive Income | Cost of Sales
Accumulated Other Comprehensive Income (Loss), Net of Tax [Roll Forward]
Cost of sales	0	0
Financial Statement Translation | Reclassification out of Accumulated Other Comprehensive Income | Other (income) expense
Accumulated Other Comprehensive Income (Loss), Net of Tax [Roll Forward]
Other (income) expense	$ (28)	$ (14)

Acquisitions (Narrative) (Detai

Acquisitions (Narrative) (Details) - USD ($) $ / shares in Units, $ in Millions	1 Months Ended				12 Months Ended
	Dec. 31, 2020	Nov. 30, 2020	Oct. 31, 2019	Mar. 31, 2019	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018
Business Acquisition [Line Items]
Aggregate purchase price of acquisitions					$ 4,304	$ 1,096
Purchase price of acquisitions, including convertible notes		$ 5,600
Repayments of long-term debt					$ 2,297	$ 1,342	$ 669
1.625% Convertible Notes
Business Acquisition [Line Items]
Stated interest rate		1.625%
Repayments of long-term debt		$ 864
2.25% Convertible Notes
Business Acquisition [Line Items]
Stated interest rate	2.25%				2.25%
Repayments of long-term debt	$ 576
Mobius
Business Acquisition [Line Items]
Aggregate purchase price of acquisitions			$ 360
OrthoSpace, Ltd.
Business Acquisition [Line Items]
Aggregate purchase price of acquisitions				$ 110
Future regulatory and commercial milestones				$ 110
Wright
Business Acquisition [Line Items]
Aggregate purchase price of acquisitions		$ 4,100
Consideration transferred, price per share (in dollars per share)		$ 30.75
Cardan Robotics
Business Acquisition [Line Items]
Future regulatory and commercial milestones			$ 130

Acquisitions (Allocation Of The

Acquisitions (Allocation Of The Preliminary Purchase Price To The Acquired Net Assets Of Acquisitions) (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018
Business Acquisition [Line Items]
Goodwill	$ 12,778	$ 9,069	$ 8,563
Weighted average life of intangible assets	14 years	14 years
Customer relationship
Business Acquisition [Line Items]
Weighted average life of intangible assets	15 years	16 years
Developed technology and patents
Business Acquisition [Line Items]
Weighted average life of intangible assets	13 years	14 years
Mobius
Business Acquisition [Line Items]
Accounts receivable		$ 3
Inventory		6
Other assets		2
Contingent consideration		(4)
Other liabilities		(10)
Goodwill		303
Purchase price, net of cash acquired		$ 473
Weighted average life of intangible assets		12 years
Mobius | Customer relationship
Business Acquisition [Line Items]
Intangible assets:		$ 7
Mobius | Developed technology and patents
Business Acquisition [Line Items]
Intangible assets:		59
Mobius | In-process research and development
Business Acquisition [Line Items]
Intangible assets:		98
Mobius | Non-compete agreements
Business Acquisition [Line Items]
Intangible assets:		9
OrthoSpace
Business Acquisition [Line Items]
Accounts receivable		1
Inventory		1
Other assets		1
Contingent consideration		0
Other liabilities		(29)
Goodwill		114
Purchase price, net of cash acquired		$ 208
Weighted average life of intangible assets		18 years
OrthoSpace | Customer relationship
Business Acquisition [Line Items]
Intangible assets:		$ 0
OrthoSpace | Developed technology and patents
Business Acquisition [Line Items]
Intangible assets:		120
OrthoSpace | In-process research and development
Business Acquisition [Line Items]
Intangible assets:		0
OrthoSpace | Non-compete agreements
Business Acquisition [Line Items]
Intangible assets:		$ 0
Wright
Business Acquisition [Line Items]
Accounts receivable	$ 127
Deferred income tax assets	371
Inventory	485
Other assets	344
Debt	(1,447)
Deferred income tax liabilities	(511)
Product liabilities	(192)
Other liabilities	(288)
Goodwill	3,428
Purchase price, net of cash acquired	$ 4,081
Weighted average life of intangible assets	12 years
Wright | Customer and distributor relationships
Business Acquisition [Line Items]
Intangible assets:	$ 181
Wright | Developed technology and patents
Business Acquisition [Line Items]
Intangible assets:	1,523
Wright | Trade name
Business Acquisition [Line Items]
Intangible assets:	$ 60

Contingencies and Commitments_2

Contingencies and Commitments (Narrative) (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018
Lease expense	$ 130	$ 133
Lease expense			$ 138
Minimum
Estimate of possible loss	470
Maximum
Estimate of possible loss	$ 720

Commitments and Contingencies -

Commitments and Contingencies - Lease Cost (Details) - USD ($) $ in Millions	Dec. 31, 2020	Dec. 31, 2019
Lessee, Lease, Description [Line Items]
Right-of-use assets	$ 423	$ 384
Weighted-average remaining lease term	5 years 7 months 6 days	6 years 2 months 12 days
Weighted-average discount rate	2.57%	3.34%
Other current liabilities
Lessee, Lease, Description [Line Items]
Lease liabilities, current	$ 109	$ 86
Other noncurrent liabilities
Lessee, Lease, Description [Line Items]
Lease liabilities, non-current	$ 325	$ 301

Contingencies and Commitments_3

Contingencies and Commitments (Future Purchase Obligations and Minimum Lease Payments) (Details) $ in Millions	Dec. 31, 2020USD ($)
Commitments and Contingencies Disclosure [Abstract]
2021	$ 761
2022	2
2023	1,670
2024	1,636
2025	1,400
Thereafter	8,646
Purchase obligations
2021	1,294
2022	76
2023	58
2024	52
2025	52
Thereafter	55
Minimum lease payments
2021	110
2022	87
2023	65
2024	38
2025	30
Thereafter	$ 90

Goodwill and Other Intangible_3

Goodwill and Other Intangible Assets (Summary of the Company's Other Intangible Assets) (Details) - USD ($)	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019
Goodwill and Intangible Assets Disclosure [Abstract]
Goodwill, impairment loss	$ 0	$ 0
Acquired Finite-Lived Intangible Assets [Line Items]
Weighted Average Amortization Period (Years)	14 years	14 years
Gross Carrying Amount	$ 8,656,000,000	$ 6,836,000,000
Less Accumulated Amortization	3,102,000,000	2,609,000,000
Net Carrying Amount	$ 5,554,000,000	$ 4,227,000,000
Developed technologies
Acquired Finite-Lived Intangible Assets [Line Items]
Weighted Average Amortization Period (Years)	13 years	14 years
Gross Carrying Amount	$ 5,305,000,000	$ 3,731,000,000
Less Accumulated Amortization	1,573,000,000	1,271,000,000
Net Carrying Amount	$ 3,732,000,000	$ 2,460,000,000
Customer relationships
Acquired Finite-Lived Intangible Assets [Line Items]
Weighted Average Amortization Period (Years)	15 years	16 years
Gross Carrying Amount	$ 2,352,000,000	$ 2,160,000,000
Less Accumulated Amortization	988,000,000	848,000,000
Net Carrying Amount	$ 1,364,000,000	$ 1,312,000,000
Patents
Acquired Finite-Lived Intangible Assets [Line Items]
Weighted Average Amortization Period (Years)	12 years	11 years
Gross Carrying Amount	$ 346,000,000	$ 348,000,000
Less Accumulated Amortization	278,000,000	265,000,000
Net Carrying Amount	$ 68,000,000	$ 83,000,000
Trademarks
Acquired Finite-Lived Intangible Assets [Line Items]
Weighted Average Amortization Period (Years)	17 years	18 years
Gross Carrying Amount	$ 428,000,000	$ 362,000,000
Less Accumulated Amortization	162,000,000	136,000,000
Net Carrying Amount	266,000,000	226,000,000
In-process research and development
Acquired Finite-Lived Intangible Assets [Line Items]
Gross Carrying Amount	97,000,000	110,000,000
Less Accumulated Amortization	0	0
Net Carrying Amount	$ 97,000,000	$ 110,000,000
Other
Acquired Finite-Lived Intangible Assets [Line Items]
Weighted Average Amortization Period (Years)	8 years	8 years
Gross Carrying Amount	$ 128,000,000	$ 125,000,000
Less Accumulated Amortization	101,000,000	89,000,000
Net Carrying Amount	$ 27,000,000	$ 36,000,000

Goodwill and Other Intangible_4

Goodwill and Other Intangible Assets (Changes in Net Carrying Amount of Goodwill by Segment) (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019
Goodwill [Roll Forward]
Goodwill, Beginning balance	$ 9,069	$ 8,563
Additions and adjustments	3,559	547
Foreign exchange	150	(41)
Goodwill, Ending balance	12,778	9,069
Orthopaedics
Goodwill [Roll Forward]
Goodwill, Beginning balance	2,386	2,399
Additions and adjustments	3,551	0
Foreign exchange	67	(13)
Goodwill, Ending balance	6,004	2,386
MedSurg
Goodwill [Roll Forward]
Goodwill, Beginning balance	3,799	3,581
Additions and adjustments	1	229
Foreign exchange	31	(11)
Goodwill, Ending balance	3,831	3,799
Neuro and Spine
Goodwill [Roll Forward]
Goodwill, Beginning balance	2,884	2,583
Additions and adjustments	7	318
Foreign exchange	52	(17)
Goodwill, Ending balance	$ 2,943	$ 2,884

Goodwill and Other Intangible_5

Goodwill and Other Intangible Assets (Estimated Amortization Expense) (Details) $ in Millions	Dec. 31, 2020USD ($)
Goodwill and Intangible Assets Disclosure [Abstract]
2021	$ 600
2022	588
2023	567
2024	540
2025	$ 518

Capital Stock (Narrative) (Deta

Capital Stock (Narrative) (Details) - USD ($) $ / shares in Units, $ in Millions	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018
Capital Stock [Line Items]
Common and Preferred Stock, shares authorized (in shares)	1,000,500,000
Preferred Stock, Shares Authorized	500,000
Preferred stock, par per share	$ 1
Common stock, authorized (in shares)	1,000,000,000
Common stock, par value (in dollars per share)	$ 0.10	$ 0.10
Preferred stock, outstanding (in shares)	0
Remaining shares authorized to be repurchased	$ 1,033
Capital shares reserved for future issuance	28,000,000	31,000,000
Aggregate intrinsic value of options exercised	$ 258	$ 294	$ 247
Options exercised during period, exercise price range, lower range limit	$ 53.60
Options exercised during period, exercise price range, upper range limit	$ 216.35
Compensation cost not yet recognized	$ 99
Compensation cost not yet recognized, period for recognized	1 year 4 months 24 days
Restricted Stock Units (RSUs)
Capital Stock [Line Items]
Compensation cost not yet recognized	$ 68
Compensation cost not yet recognized, period for recognized	1 year
Weighted average grant date fair value, Granted (in dollars per share)	$ 208.96	$ 175.96
Shares vested during the period	$ 55
Performance Stock Units (PSUs)
Capital Stock [Line Items]
Compensation cost not yet recognized	$ 16
Compensation cost not yet recognized, period for recognized	1 year
Weighted average grant date fair value, Granted (in dollars per share)	$ 217.73
Shares vested during the period	$ 9
Employee Stock Purchase Plans
Capital Stock [Line Items]
Percentage of closing stock price under ESPP	95.00%
Shares issued under the ESPP	209,837	166,758

Capital Stock (Option Grant Ass

Capital Stock (Option Grant Assumptions) (Details) - $ / shares	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018
Capital Stock [Abstract]
Weighted-average fair value per share	$ 39.34	$ 36.30	$ 28.52
Risk-free interest rate	1.40%	2.60%	2.70%
Expected dividend yield	1.00%	1.10%	1.20%
Expected stock price volatility	18.90%	18.30%	16.80%
Expected option life (years)	5 years 9 months 18 days	5 years 10 months 24 days	6 years

Capital Stock (Summary of Stock

Capital Stock (Summary of Stock Option Activity) (Details) $ / shares in Units, shares in Millions, $ in Millions	12 Months Ended
	Dec. 31, 2020USD ($)$ / sharesshares
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]
Shares, Options outstanding at January 1 (in shares) | shares	12.8
Shares, Granted (in shares) | shares	1.8
Shares, Exercised (in shares) | shares	(2)
Shares, Cancelled (in shares) | shares	(0.4)
Shares, Options outstanding at December 31 (in shares) | shares	12.2
Shares, Exercisable at December 31 (in shares) | shares	6.8
Shares, Options expected to vest (in shares) | shares	4.9
Weighted Average Exercise Price
Weighted average exercise price, Options outstanding at January 1 (in dollars per share) | $ / shares	$ 113.10
Weighted average exercise price, Granted (in dollars per share) | $ / shares	216.28
Weighted average exercise price, Exercised (in dollars per share) | $ / shares	83.75
Weighted average exercise price, Cancelled (in dollars per share) | $ / shares	162.98
Weighted average exercise price, Options outstanding at December 31 (in dollars per share) | $ / shares	131.72
Weighted average exercise price, Exercisable at December 31 (in dollars per share) | $ / shares	99.09
Weighted average exercise price, Options expected to vest (in dollars per share) | $ / shares	$ 171.06
Share-based Compensation Arrangement by Share-based Payment Award, Options, Additional Disclosures [Abstract]
Weighted-average remaining contractual term, Options outstanding at December 31 (in years)	5 years 10 months 24 days
Weighted-average remaining contractual term, Exercisable at December 31 (in years)	4 years 4 months 24 days
Weighted-average remaining contractual term, Options expected to vest (in years)	7 years 8 months 12 days
Aggregate intrinsic value, Options outstanding at December 31 | $	$ 1,388.1
Aggregate intrinsic value, Exercisable at December 31 | $	995.7
Aggregate intrinsic value, Options expected to vest | $	$ 364.3

Capital Stock (Summary of RSU a

Capital Stock (Summary of RSU and PSU Activity) (Details) - $ / shares shares in Millions	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019
Restricted Stock Units (RSUs)
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]
Shares, Nonvested at January 1 (in shares)	0.8
Shares, Granted (in shares)	0.4
Shares, Vested (in shares)	(0.4)
Shares, Cancelled (in shares)	0
Shares, Nonvested at December 31 (in shares)	0.8	0.8
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]
Weighted average grant date fair value, Outstanding at January 1 (in dollars per share)	$ 158.80
Weighted average grant date fair value, Granted (in dollars per share)	208.96	$ 175.96
Weighted average grant date fair value, Vested (in dollars per share)	149.09
Weighted average grant date fair value, Cancelled (in dollars per share)	154.38
Weighted average grant date fair value, Outstanding at December 31 (in dollars per share)	$ 187.72	$ 158.80
Performance Stock Units (PSUs)
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]
Shares, Nonvested at January 1 (in shares)	0.2
Shares, Granted (in shares)	0.1
Shares, Vested (in shares)	(0.1)
Shares, Cancelled (in shares)	0
Shares, Nonvested at December 31 (in shares)	0.2	0.2
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]
Weighted average grant date fair value, Outstanding at January 1 (in dollars per share)	$ 152.44
Weighted average grant date fair value, Granted (in dollars per share)	217.73
Weighted average grant date fair value, Vested (in dollars per share)	122.41
Weighted average grant date fair value, Cancelled (in dollars per share)	166.99
Weighted average grant date fair value, Outstanding at December 31 (in dollars per share)	$ 185.46	$ 152.44

Debt and Credit Facilities (Nar

Debt and Credit Facilities (Narrative) (Details) € in Millions	Apr. 30, 2020USD ($)	Nov. 30, 2020USD ($)	Jun. 30, 2020USD ($)	Dec. 31, 2020USD ($)	Dec. 31, 2019USD ($)	Dec. 31, 2018USD ($)	Nov. 30, 2020EUR (€)	Nov. 30, 2020USD ($)	Mar. 31, 2020	Jan. 15, 2020USD ($)
Line of Credit Facility [Line Items]
Commercial paper				$ 0
Debt instrument, repurchased face amount | €							€ 300
Interest expense, debt				$ 315,000,000	$ 287,000,000	$ 264,000,000
Revolving Credit Facility
Line of Credit Facility [Line Items]
Leverage ratio	4.5			5					3.5
Commercial Paper
Line of Credit Facility [Line Items]
Maximum borrowing capacity				$ 1,500,000,000
Maturities of time deposits				397 days
Senior Unsecured Notes 4.375% Due 2020
Line of Credit Facility [Line Items]
Debt instrument, repurchased face amount										$ 500,000,000
Stated interest rate				4.375%						4.375%
Credit Agreement | Revolving Credit Facility
Line of Credit Facility [Line Items]
Maximum borrowing capacity	$ 1,500,000,000
Debt instrument, term	364 days
Senior Unsecured Notes, 1.150% Due 2025
Line of Credit Facility [Line Items]
Stated interest rate			1.15%	1.15%
Proceeds from issuance of debt			$ 650,000,000
Senior Unsecured Notes, 1.950% Due 2030
Line of Credit Facility [Line Items]
Stated interest rate			1.95%	1.95%
Proceeds from issuance of debt			$ 1,000,000,000
Senior Unsecured Notes, 2.900% due 2050
Line of Credit Facility [Line Items]
Stated interest rate			2.90%	2.90%
Proceeds from issuance of debt			$ 650,000,000
Senior Unsecured Notes 0.600% due 2023
Line of Credit Facility [Line Items]
Stated interest rate				0.60%			0.60%	0.60%
Proceeds from issuance of debt		$ 600,000,000
Term Loan
Line of Credit Facility [Line Items]
Long-term debt				$ 400,000,000	$ 0			$ 400,000,000
Term Loan | London Interbank Offered Rate (LIBOR)
Line of Credit Facility [Line Items]
Basis spread on variable rate		1.125%
Floating Rate Notes due 2020
Line of Credit Facility [Line Items]
Debt instrument, repurchased face amount | €							€ 300

Debt and Credit Facilities (Mat

Debt and Credit Facilities (Maturities Of Long-Term Debt Disclosures) (Details) - USD ($)	Dec. 31, 2020	Nov. 30, 2020	Jun. 30, 2020	Jan. 15, 2020	Dec. 31, 2019
Other long-term debt	$ 16,000,000				$ 26,000,000
Total debt	13,991,000,000				11,090,000,000
Current maturities of debt	761,000,000				859,000,000
Total long-term debt	13,230,000,000				10,231,000,000
Unamortized debt issuance costs	71,000,000				58,000,000
Borrowing capacity on existing facilities	2,903,000,000				1,546,000,000
Fair value of senior unsecured notes	$ 15,022,000,000				11,910,000,000
Senior Unsecured Notes 4.375% due 2020
Stated interest rate	4.375%			4.375%
Unsecured debt	$ 0				500,000,000
Senior Unsecured Notes, Variable, due 2020
Unsecured debt	$ 0				333,000,000
Senior Unsecured Notes 2.625% due 2021
Stated interest rate	2.625%
Unsecured debt	$ 750,000,000				749,000,000
Senior Unsecured Notes, 1.125%, due 2023
Stated interest rate	1.125%
Unsecured debt	$ 668,000,000				609,000,000
Senior Unsecured Notes 0.600% due 2023
Stated interest rate	0.60%	0.60%
Unsecured debt	$ 597,000,000				0
Senior Unsecured Notes 3.375% due 2024
Stated interest rate	3.375%
Unsecured debt	$ 590,000,000				587,000,000
Senior Unsecured Notes 0.250% due 2024
Stated interest rate	0.25%
Unsecured debt	$ 1,030,000,000				938,000,000
Senior Unsecured Notes, 1.150% Due 2025
Stated interest rate	1.15%		1.15%
Unsecured debt	$ 644,000,000				0
Senior Unsecured Notes 3.375% due 2025
Stated interest rate	3.375%
Unsecured debt	$ 747,000,000				746,000,000
Senior Unsecured Notes 3.50% due 2026
Stated interest rate	3.50%
Unsecured debt	$ 992,000,000				991,000,000
Senior Unsecured Notes,2.125%, due 2027
Stated interest rate	2.125%
Unsecured debt	$ 909,000,000				829,000,000
Senior Unsecured Notes 3.650% due 2028
Stated interest rate	3.65%
Unsecured debt	$ 596,000,000				596,000,000
Senior Unsecured Notes 0.750% due 2029
Stated interest rate	0.75%
Unsecured debt	$ 969,000,000				884,000,000
Senior Unsecured Notes, 1.950% Due 2030
Stated interest rate	1.95%		1.95%
Unsecured debt	$ 989,000,000				0
Senior Unsecured Notes, 2.625% due 2030
Stated interest rate	2.625%
Unsecured debt	$ 782,000,000				712,000,000
Senior Unsecured Notes 1.000% due 2031
Stated interest rate	1.00%
Unsecured debt	$ 903,000,000				823,000,000
Senior Unsecured Notes 4.10% due 2043
Stated interest rate	4.10%
Unsecured debt	$ 392,000,000				391,000,000
Senior Unsecured Notes 4.375% due 2044
Stated interest rate	4.375%
Unsecured debt	$ 395,000,000				395,000,000
Senior Unsecured Notes 4.625% due 2046
Stated interest rate	4.625%
Unsecured debt	$ 981,000,000				981,000,000
Senior Unsecured Notes, 2.900% due 2050
Stated interest rate	2.90%		2.90%
Unsecured debt	$ 641,000,000				0
Term Loan
Long-term debt	$ 400,000,000	$ 400,000,000			$ 0

Income Taxes (Narrative) (Detai

Income Taxes (Narrative) (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018
Income Tax Contingency [Line Items]
Effective income tax, percent	18.20%	18.70%	(50.80%)
Interest expense and penalties included in other income (expense), net	$ (35)	$ (9)	$ (9)
Net operating loss carryforward recognized	41	50	$ 31
Accrued interest and penalties	133	94
Operating loss carryforwards	1,642
Operating loss carryforwards, subject to full valuation allowance	410
Unrecognized tax benefits, interest on income tax expense	456	$ 468
Wright
Income Tax Contingency [Line Items]
Operating loss carryforwards	1,409
Operating loss carryforwards, subject to full valuation allowance	405
United States
Income Tax Contingency [Line Items]
Operating loss carryforwards	1,509
Foreign Tax Authority
Income Tax Contingency [Line Items]
Operating loss carryforwards	132
Tax credit carryforward, amount	97
Tax credit carryforward, valuation allowance	$ 93

Income Taxes (Schedule of Recon

Income Taxes (Schedule of Reconciliation of U.S. Statutory Income Tax Rate to Company's Effective Income Tax Rate from Continuing Operations) (Details)	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018
Income Tax Disclosure [Abstract]
United States federal statutory rate	21.00%	21.00%	21.00%
United States state and local income taxes, less federal deduction	0.10%	1.70%	0.40%
International operations	(3.30%)	(4.60%)	(6.50%)
Effective Income Tax Rate Reconciliation, Tax Cuts and Jobs Act, Transition Tax on Accumulated Foreign Earnings, Percent	0	0	0.022
Effective Income Tax Rate Reconciliation, Tax Cuts and Jobs Act, Percent	0	0	(0.006)
Tax related to repatriation of foreign earnings	3.00%	(0.50%)	0.50%
Intellectual property transfer	(1.40%)	3.50%	(63.80%)
Other	(1.20%)	(2.40%)	(4.00%)
Effective income tax rate, total	18.20%	18.70%	(50.80%)

Income Taxes (Schedule of Earni

Income Taxes (Schedule of Earnings before Income Taxes) (Details) - USD ($) $ in Millions	3 Months Ended								12 Months Ended
	Dec. 31, 2020	Sep. 30, 2020	Jun. 30, 2020	Mar. 31, 2020	Dec. 31, 2019	Sep. 30, 2019	Jun. 30, 2019	Mar. 31, 2019	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018
Income Tax Disclosure [Abstract]
United States									$ 239	$ 366	$ 509
International									1,715	2,196	1,847
Earnings before income taxes	$ 671	$ 780	$ (87)	$ 590	$ 936	$ 581	$ 565	$ 480	$ 1,954	$ 2,562	$ 2,356

Income Taxes (Schedule of Provi

Income Taxes (Schedule of Provision for Income Taxes) (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018
Current income tax expense:
United States federal	$ 80	$ (17)	$ 178
United States state and local	20	46	30
International	207	324	177
Total current income tax expense	307	353	385
Deferred income tax (benefit) expense:
United States federal	1	10	(44)
United States state and local	(25)	(1)	(20)
International	72	117	(1,518)
Total deferred income tax (benefit) expense	48	126	(1,582)
Total income tax (benefit) expense	$ 355	$ 479	$ (1,197)

Income Taxes (Schedule of Diffe

Income Taxes (Schedule of Difference in Income Tax Effects Comprising Company's Deferred Income Tax Assets and Liabilities) (Details) - USD ($) $ in Millions	Dec. 31, 2020	Dec. 31, 2019
Deferred income tax assets:
Inventories	$ 434	$ 415
Product-related liabilities	48	57
Other accrued expenses	512	221
Depreciation and amortization	1,269	1,363
State income taxes	108	65
Share-based compensation	56	49
Net operating loss carryforwards	373	95
Other	263	207
Total deferred income tax assets	3,063	2,472
Less valuation allowances	(203)	(75)
Net deferred income tax assets	2,860	2,397
Deferred income tax liabilities:
Depreciation and amortization	(1,286)	(893)
Undistributed earnings	(161)	(37)
Other	0	0
Total deferred income tax liabilities	(1,447)	(930)
Net deferred income tax assets	1,413	1,467
Noncurrent deferred income tax assets	1,530	1,575
Noncurrent liabilities—Other liabilities	$ (117)	$ (108)

Income Taxes (Schedule of Unres

Income Taxes (Schedule of Unresolved Income Tax Positions) (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019
Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward]
Beginning uncertain tax positions	$ 472	$ 528
Increases related to current year income tax positions	12	62
Increases related to prior year income tax positions	5	5
Settlements and resolutions of income tax audits	(41)	(78)
Statute of limitations expirations and other	(7)	(40)
Foreign currency translation	16
Foreign currency translation		(5)
Ending uncertain tax positions	$ 457	$ 472

Retirement Plans (Schedule of D

Retirement Plans (Schedule of Defined Contribution Plan Disclosures) (Details) - USD ($) shares in Millions, $ in Millions	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018
Retirement Benefits [Abstract]
Plan expense	$ 235	$ 205	$ 180
Expense funded with Stryker common stock	34	31	29
Stryker common stock held by plan, amount	$ 542	$ 470	$ 358
Stryker common stock held by plan, shares	2.2	2.2	2.3
Stryker common stock held by plan, value as a percentage of total plan assets	11.00%	12.00%	12.00%

Retirement Plans (Schedule of F

Retirement Plans (Schedule of Funded Status and Components of the Amounts Recognized in the Consolidated Balance Sheets and in Accumulated Other Comprehensive Gain (Loss), Before the Effect of Income Taxes) (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018
Components of Net Periodic Pension Cost
Service cost	$ (63)	$ (41)	$ (44)
Interest cost	(8)	(12)	(11)
Expected return on plan assets	13	12	12
Amortization of prior service cost and transition amount	1	1	1
Recognized actuarial loss	(13)	(9)	(11)
Net periodic benefit cost	(70)	(49)	(53)
Net actuarial gain (loss)	(117)	(74)	11
Recognized net actuarial loss	13	9	10
Prior service cost and transition amount	(1)	(1)	(1)
Total recognized in OCI	(105)	(66)	20
Total recognized in net periodic benefit cost and OCI	$ (175)	$ (115)	$ (33)
Defined Benefit Plan, Assumptions Used in Calculations [Abstract]
Discount rate	1.00%	1.90%	1.80%
Expected return on plan assets	2.90%	3.50%	3.30%
Expected return on plan assets	2.90%	2.90%	2.80%
Weighted-average discount rate used to determine projected benefit obligations	0.80%	1.00%	1.90%
Defined Benefit Plan, Information about Plan Assets [Abstract]
Fair value of plan assets	$ 522	$ 428
Benefit obligations	(1,118)	(869)	$ (735)
Funded status	(596)	(441)
Current liabilities—accrued compensation	(2)	(2)
Noncurrent liabilities—other liabilities	(594)	(439)
Unrecognized net actuarial loss	(346)	(241)
Accumulated Defined Benefit Plans Adjustment, Net Prior Service Attributable to Parent
Defined Benefit Plan, Information about Plan Assets [Abstract]
Unrecognized prior service credit	8	9
Unrecognized net actuarial loss	$ (354)	$ (250)

Retirement Plans (Schedule of C

Retirement Plans (Schedule of Change in Benefit Obligations (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018
Defined Benefit Plan, Change in Benefit Obligation [Roll Forward]
Beginning projected benefit obligations	$ 869	$ 735
Service cost	63	41	$ 44
Interest cost	8	12	11
Foreign exchange impact	80	(12)
Employee contributions	8	6
Actuarial (gains) losses	110	116
Acquisition	0	0
Benefits paid	(20)	(29)
Ending projected benefit obligations	1,118	869	$ 735
Ending accumulated benefit obligations	$ 1,056	$ 830

Retirement Plans (Change in Pla

Retirement Plans (Change in Plan Assets) (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019
Defined Benefit Plan, Change in Fair Value of Plan Assets [Roll Forward]
Beginning fair value of plan assets	$ 428	$ 376
Actual return	30	52
Employer contributions	33	25
Employee contributions	8	6
Foreign exchange impact	37	(5)
Acquisition	0	0
Benefits paid	(14)	(26)
Ending fair value of plan assets	$ 522	$ 428

Retirement Plans (Schedule of T

Retirement Plans (Schedule of Target and Actual Allocation of Plan Assets) (Details)	Dec. 31, 2020	Dec. 31, 2019
Defined Benefit Plan Disclosure [Line Items]
Target plan asset allocations	100.00%
Actual plan asset allocations	100.00%	100.00%
Equity securities
Defined Benefit Plan Disclosure [Line Items]
Target plan asset allocations	20.00%
Actual plan asset allocations	23.00%	22.00%
Debt securities
Defined Benefit Plan Disclosure [Line Items]
Target plan asset allocations	45.00%
Actual plan asset allocations	44.00%	44.00%
Other
Defined Benefit Plan Disclosure [Line Items]
Target plan asset allocations	35.00%
Actual plan asset allocations	33.00%	34.00%

Retirement Plans (Schedule of V

Retirement Plans (Schedule of Valuation of the Company's Pension Plan Assets by Pricing Categories) (Details) - USD ($) $ in Millions	Dec. 31, 2020	Dec. 31, 2019
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	$ 522	$ 428
(Level 1)
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	46	37
(Level 2)
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	372	311
(Level 3)
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	104	80
Cash and cash equivalents
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	14	7
Cash and cash equivalents | (Level 1)
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	14	7
Cash and cash equivalents | (Level 2)
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	0	0
Cash and cash equivalents | (Level 3)
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	0	0
Equity securities
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	131	109
Equity securities | (Level 1)
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	23	23
Equity securities | (Level 2)
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	108	86
Equity securities | (Level 3)
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	0	0
Corporate debt securities
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	203	176
Corporate debt securities | (Level 1)
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	2	3
Corporate debt securities | (Level 2)
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	201	173
Corporate debt securities | (Level 3)
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	0	0
Other
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	174	136
Other | (Level 1)
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	7	4
Other | (Level 2)
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	63	52
Other | (Level 3)
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	$ 104	$ 80

Retirement Plans (Narrative) (D

Retirement Plans (Narrative) (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019
Defined Benefit Plan Disclosure [Line Items]
Actual return	$ 30	$ 52
Estimated future employer contributions in next fiscal year	30
(Level 3)
Defined Benefit Plan Disclosure [Line Items]
Actual return	$ 24

Retirement Plans (Expected Bene

Retirement Plans (Expected Benefit Payments) (Details) $ in Millions	Dec. 31, 2020USD ($)
Retirement Benefits [Abstract]
2021	$ 22
2022	21
2023	21
2024	22
2025	24
2026-2030	$ 134

Summary of Quarterly Data (Un_3

Summary of Quarterly Data (Unaudited) (Details) - USD ($) $ / shares in Units, $ in Millions	3 Months Ended								12 Months Ended
	Dec. 31, 2020	Sep. 30, 2020	Jun. 30, 2020	Mar. 31, 2020	Dec. 31, 2019	Sep. 30, 2019	Jun. 30, 2019	Mar. 31, 2019	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018
Quarterly Financial Data [Abstract]
Net sales	$ 4,262	$ 3,737	$ 2,764	$ 3,588	$ 4,131	$ 3,587	$ 3,650	$ 3,516	$ 14,351	$ 14,884	$ 13,601
Gross profit	2,717	2,461	1,548	2,331	2,703	2,330	2,380	2,283	9,057	9,696	8,938
Earnings (loss) before income taxes	671	780	(87)	590	936	581	565	480	1,954	2,562	2,356
Net earnings (loss)	$ 568	$ 621	$ (83)	$ 493	$ 725	$ 466	$ 480	$ 412	$ 1,599	$ 2,083	$ 3,553
Basic net earnings per share of common stock (in dollars per share)	$ 1.51	$ 1.66	$ (0.22)	$ 1.32	$ 1.94	$ 1.24	$ 1.29	$ 1.10	$ 4.26	$ 5.57	$ 9.50
Diluted net earnings per share of common stock (in dollars per share)	1.49	1.63	(0.22)	1.30	1.90	1.23	1.26	1.09	$ 4.20	$ 5.48	$ 9.34
Dividends declared per share of common stock (in dollars per share)	$ 0.63	$ 0.575	$ 0.575	$ 0.575	$ 0.575	$ 0.52	$ 0.52	$ 0.52

Segment and Geographic Data (Sa

Segment and Geographic Data (Sales And Other Financial Information By Business Segment) (Details) $ in Millions	3 Months Ended								12 Months Ended
	Dec. 31, 2020USD ($)	Sep. 30, 2020USD ($)	Jun. 30, 2020USD ($)	Mar. 31, 2020USD ($)	Dec. 31, 2019USD ($)	Sep. 30, 2019USD ($)	Jun. 30, 2019USD ($)	Mar. 31, 2019USD ($)	Dec. 31, 2020USD ($)segment	Dec. 31, 2019USD ($)	Dec. 31, 2018USD ($)
Segment Reporting [Abstract]
Number of Reportable Segments | segment									3
Segment Reporting Information [Line Items]
Net sales	$ 4,262	$ 3,737	$ 2,764	$ 3,588	$ 4,131	$ 3,587	$ 3,650	$ 3,516	$ 14,351	$ 14,884	$ 13,601
Depreciation and amortization									1,076	1,044	966
Segment net earnings (loss)									2,223	2,713	2,537
Amortization of intangible assets									(472)	(464)	(417)
Net earnings (loss)	$ 568	$ 621	$ (83)	$ 493	$ 725	$ 466	$ 480	$ 412	1,599	2,083	3,553
MedSurg
Segment Reporting Information [Line Items]
Net sales									6,400	6,492	6,045
Neuro and Spine
Segment Reporting Information [Line Items]
Net sales									2,992	3,140	2,565
Operating Segments
Segment Reporting Information [Line Items]
Depreciation and amortization									954	945	811
Segment operating income									4,002	4,388	3,948
Operating Segments | Orthopaedics
Segment Reporting Information [Line Items]
Net sales									4,959	5,252	4,991
Depreciation and amortization									344	348	350
Segment net earnings (loss)									1,518	1,907	1,804
Operating Segments | MedSurg
Segment Reporting Information [Line Items]
Net sales									6,400	6,492	6,045
Depreciation and amortization									362	379	285
Segment net earnings (loss)									1,837	1,642	1,444
Operating Segments | Neuro and Spine
Segment Reporting Information [Line Items]
Net sales									2,992	3,140	2,565
Depreciation and amortization									248	218	176
Segment net earnings (loss)									647	839	700
Corporate
Segment Reporting Information [Line Items]
Depreciation and amortization									122	99	155
Segment Reconciling Items
Segment Reporting Information [Line Items]
Segment operating income									(503)	(480)	(431)
Acquisition and integration-related charges									(242)	(275)	(123)
Amortization of intangible assets									(472)	(464)	(417)
Restructuring-related and other charges									(458)	(226)	(220)
Medical device regulations									(81)	(62)	(12)
Recall-related matters									(17)	(192)	(23)
Regulatory and legal matters									(6)	24	(185)
Net earnings (loss)									$ 2,223	$ 2,713	$ 2,537

Segment and Geographic Data (Se

Segment and Geographic Data (Segment Information) (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018
Segment Reporting Information [Line Items]
Assets	$ 34,330	$ 30,167	$ 27,229
Capital Expenditures During Period	487	649	572
Operating Segments
Segment Reporting Information [Line Items]
Assets	33,340	28,797	26,550
Capital Expenditures During Period	342	419	382
Operating Segments | Orthopaedics
Segment Reporting Information [Line Items]
Assets	14,910	9,085	8,873
Capital Expenditures During Period	140	125	134
Operating Segments | MedSurg
Segment Reporting Information [Line Items]
Assets	17,901	12,066	10,417
Capital Expenditures During Period	174	265	217
Operating Segments | Neuro and Spine
Segment Reporting Information [Line Items]
Assets	529	7,646	7,260
Capital Expenditures During Period	28	29	31
Corporate
Segment Reporting Information [Line Items]
Assets	990	1,370	679
Capital Expenditures During Period	$ 145	$ 230	$ 190

Segment and Geographic Data (Ge

Segment and Geographic Data (Geographic Information on Net Sales and Long-Lived Assets) (Details) - USD ($) $ in Millions	3 Months Ended								12 Months Ended
	Dec. 31, 2020	Sep. 30, 2020	Jun. 30, 2020	Mar. 31, 2020	Dec. 31, 2019	Sep. 30, 2019	Jun. 30, 2019	Mar. 31, 2019	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018
Segment Reporting Information [Line Items]
Net sales	$ 4,262	$ 3,737	$ 2,764	$ 3,588	$ 4,131	$ 3,587	$ 3,650	$ 3,516	$ 14,351	$ 14,884	$ 13,601
Net Property, Plant & Equipment	2,752				2,567				2,752	2,567
United States
Segment Reporting Information [Line Items]
Net sales									10,455	10,957	9,848
Net Property, Plant & Equipment	1,645				1,561				1,645	1,561
Europe, Middle East, Africa
Segment Reporting Information [Line Items]
Net sales									1,818	1,888	1,793
Net Property, Plant & Equipment	938				838				938	838
Asia Pacific
Segment Reporting Information [Line Items]
Net sales									1,630	1,617	1,532
Net Property, Plant & Equipment	91				95				91	95
Other foreign countries
Segment Reporting Information [Line Items]
Net sales									448	422	$ 428
Net Property, Plant & Equipment	$ 78				$ 73				$ 78	$ 73

Asset Impairments (Details)

Asset Impairments (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018
Property, Plant and Equipment [Line Items]
Asset impairments	$ 215	$ 16	$ 14
Property, Plant and Equipment, Other Types
Property, Plant and Equipment [Line Items]
Asset impairments	$ 195

Schedule II Valuation and Quali

Schedule II Valuation and Qualifying Accounts (Details) - SEC Schedule, 12-09, Allowance, Notes Receivable [Member] - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018
SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Line Items]
Balance at Beginning of Period	$ 88	$ 64	$ 59
Charged to Costs & Expenses	65	39	20
Uncollectible Amounts Written Off, Net of Recoveries	22	13	14
Effect of Changes in Foreign Currency Exchange Rates	0	2	1
Balance at End of Period	$ 131	$ 88	$ 64